Novel bacteriophage, bacteriophage cocktail comprising same, and uses thereof
The bacteriophages MXP1001 and MXP1002 address multidrug-resistant Pseudomonas aeruginosa infections by lysing strains and enhancing antibiotic susceptibility, offering a novel therapeutic approach to manage infections and biofilm formation.
Patent Information
- Application Number
- PCT/KR2026/096720
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
The increasing incidence of multidrug-resistant Pseudomonas aeruginosa infections poses a clinical challenge, requiring therapies with different mechanisms of action, as conventional antibiotics face limitations due to resistance and side effects, necessitating the development of bacteriophage cocktails and combination therapies to enhance antimicrobial effects.
Development of bacteriophages MXP1001 and MXP1002, deposited under accession numbers KCCM13247P and KCCM13335P, respectively, which can lyse Pseudomonas aeruginosa strains, including antibiotic-resistant ones, and enhance antibiotic susceptibility by acting on the peptidoglycan layer, potentially used in combination with antibiotics to inhibit biofilm formation and improve treatment efficacy.
The bacteriophages MXP1001 and MXP1002 enhance the susceptibility of Pseudomonas aeruginosa to antibiotics, including enhancing antibiotic efficacy by improving access to the target site of the antibiotic, potentially reducing the minimum inhibitory concentration of the antibiotic, and inhibiting biofilm formation, and improving the susceptibility of Pseudomonas aeruginosa, including enhancing antibiotic susceptibility, including inhibiting biofilm formation, and improving the susceptibility of Pseudomonas aeruginosa, including enhancing antibiotic susceptibility, including enhancing antibiotic susceptibility, including enhancing antibiotic susceptibility, including enhancing antibiotic susceptibility, and antibiotic susceptibility, including enhancing antibiotic efficacy, including enhancing antibiotic efficacy, by including enhancing the antibiotic efficacy, including enhancing antibiotic efficacy, including enhancing antibiotic synergy, including synergistically with the antibiotic synergy.
Smart Images

Figure KR2026096720_12112026_PF_FP_ABST
Abstract
Description
Novel bacteriophage, bacteriophage cocktail containing the same, and uses thereof
[0001] The present invention relates to bacteriophages and bacteriophage cocktails having lytic activity against Pseudomonas aeruginosa, particularly multidrug-resistant Pseudomonas aeruginosa. Furthermore, the present invention relates to combination therapy comprising antibiotics and bacteriophages having lytic activity against Pseudomonas aeruginosa, including multidrug-resistant Pseudomonas aeruginosa. Furthermore, the present invention relates to pharmaceutical compositions and / or formulations of a single bacteriophage or a bacteriophage cocktail, and their use in combination with antibiotics to treat Pseudomonas aeruginosa infections and / or diseases associated with Pseudomonas aeruginosa infections. Additionally, the present invention relates to bacteriophage-antibiotic combination therapy for drug-resistant Pseudomonas aeruginosa infections.
[0002] Pseudomonas aeruginosa is a Gram-negative bacillus and a glucose-nonfermenting bacterium that exists in natural environments such as soil, water, and sewage, and may colonize the skin, oral and respiratory mucosa of humans and animals. Pseudomonas aeruginosa is known as an opportunistic pathogenic bacterium and can cause infection in immunocompromised individuals, including infants, cancer patients, transplant patients taking immunomodulatory drugs, and HIV / AIDS patients, as well as patients with diseases such as cystic fibrosis or diabetes. In hospitalized patients, Pseudomonas aeruginosa can be transmitted by ventilators, endovascular invasive procedures, bedding, and medical personnel, and may be associated with hospital-acquired pneumonia or ventilator-associated pneumonia, infections in wound patients (e.g., burns or infections associated with diabetes), meningitis, endocarditis, or bacteremia (e.g., sepsis).
[0003] The increasing incidence of multidrug-resistant Pseudomonas aeruginosa is a growing clinical concern. Compared to individuals infected with antibiotic-susceptible strains, those infected with antibiotic-resistant Pseudomonas aeruginosa tend to have a poorer clinical course and may require antibiotics with more severe side effects. As antibiotic resistance increases globally, there is a clinical need to develop therapies with completely different mechanisms of action. Bacteriophages are organisms with a simple structure in which a protein envelope surrounds a nucleus of genetic material; this genetic material can be single-stranded or double-stranded DNA or RNA. Bacteriophages are known to be selective for specific bacteria and, without being bound by theory, can infect and kill host bacteria by attacking the peptidoglycan layer of the host bacterium's cell wall. Since the mechanism of host cell death is distinct from that of conventional synthetic antibiotics, bacteriophages can be used therapeutically against multidrug-resistant bacteria that have acquired resistance to conventional antibiotics. Furthermore, because bacteriophages do not infect eukaryotic cells, bacteriophage therapy in animals, including humans, has limited side effects.
[0004] There is a need for therapeutic methods capable of effectively managing or treating infections caused by Pseudomonas aeruginosa, particularly multidrug-resistant strains. Furthermore, there is a need for bacteriophage cocktails containing two or more potent bacteriophages to, for example, reduce the risk of resistance or lyse a wider variety of Pseudomonas aeruginosa strains. Moreover, there is a need for combination therapies involving bacteriophages and antibiotics to achieve enhanced antimicrobial effects. Additionally, research on bacteriophage-antibiotic combination therapy for drug-resistant Pseudomonas aeruginosa infections is required.
[0005] The object of the present invention is to provide bacteriophage MXP1001 deposited under accession number KCCM13247P.
[0006] Another object of the present invention is to provide bacteriophage MXP1002 deposited under accession number KCCM13335P.
[0007] Another objective of the present invention is to provide an antimicrobial composition comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0008] Another objective of the present invention is to provide a composition for inhibiting biofilm formation comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0009] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0010] Another object of the present invention is to provide a kit for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof; and instructions.
[0011] Another objective of the present invention is to provide a food composition for the prevention or improvement of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0012] Another objective of the present invention is to provide a method for preventing, treating, or improving a Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual.
[0013] Another objective of the present invention is to provide a method for enhancing antibiotic susceptibility of Pseudomonas aeruginosa, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0014] Another object of the present invention is a method for inhibiting or reducing a Pseudomonas aeruginosa biofilm comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0015] Another objective of the present invention is to provide a use for the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection using bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof capable of lysing Pseudomonas aeruginosa.
[0016] One aspect of the present invention for achieving the above objective relates to bacteriophage MXP1001, deposited under accession number KCCM13247P, which is capable of lysing Pseudomonas aeruginosa.
[0017] In the present invention, 'Pseudomonas aeruginosa' is a Gram-negative bacillus and a glucose-non-fermenting bacterium that may exist in natural environments including soil, water, and sewage, and may colonize the skin, oral and respiratory mucosa of humans and animals. Furthermore, Pseudomonas aeruginosa is an opportunistic pathogenic bacterium that can cause infection in immunocompromised subjects, such as infants, cancer patients, transplant patients taking immunomodulatory drugs, and HIV / AIDS patients, as well as patients with diseases such as cystic fibrosis or diabetes. In the case of hospitalized patients, it may be transmitted by ventilators, endovascular invasive procedures, bedding, and medical personnel, and may be associated with hospital-acquired pneumonia, ventilator-associated pneumonia, wound infection, meningitis, endocarditis, bacteremia, or sepsis.
[0018] Specifically, the bacteriophage MXP1001 may comprise a genome comprising a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% identity with respect to the nucleotide sequence of SEQ ID NO. 1.
[0019] Additionally, specifically, the above-mentioned Pseudomonas aeruginosa may be an antibiotic-resistant strain.
[0020] In the present invention, 'antibiotic resistance' refers to drug resistance that enables survival even when exposed to antibiotics, and includes mechanisms such as drug inactivation, alteration of target site, decreased uptake of antibiotics, efflux pump, and alteration of metabolic pathways. Genes causing such resistance or resistance to antibiotics can be transferred horizontally between strains through conjugation, transduction, or transformation. They may exhibit properties of complete resistance, partial resistance, or intermediate resistance to one or more antibiotics or antibiotic classes, and may include, for example, resistance to aztreonam, imipenem, meropenem, ceftazidim, or piperacillin / tazobactam, but are not limited thereto.
[0021] Specifically, the above 'antibiotic resistance' may include multidrug resistance. The above multidrug resistance may include resistance, partial resistance, or intermediate resistance to two or more antibiotics or antibiotic classes, but is not limited thereto.
[0022] In addition, specifically, the bacteriophage MXP1001 may enhance the susceptibility of Pseudomonas aeruginosa to antibiotics.
[0023] In the present invention, 'susceptibility to antibiotics' may refer to the degree to which the survival, proliferation, replication, colonization, or biofilm formation of Pseudomonas aeruginosa is inhibited or reduced in the presence of antibiotics.
[0024] In addition, in the present invention, 'enhancement of susceptibility' may mean that the antimicrobial effect of an antibiotic against Pseudomonas aeruginosa is increased by treatment with bacteriophage MXP1001 or by the combined use of bacteriophage MXP1001 and an antibiotic. For example, the enhancement of susceptibility may be confirmed by a decrease in the minimum inhibitory concentration (MIC) of the antibiotic, a superior inhibitory or killing effect on bacterial growth when treated with the same concentration of antibiotic, a decrease in antibiotic resistance or intermediate resistance, a decrease in biofilm-forming ability, or a combination thereof, but is not limited thereto.
[0025] In one embodiment, the enhancement of susceptibility may occur by bacteriophage MXP1001 acting on Pseudomonas aeruginosa to improve access to the target site of the antibiotic, weaken the defense mechanism of Pseudomonas aeruginosa, or act complementarily or synergistically with the antibiotic, but is not limited thereto.
[0026] In addition, the above antibiotics may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but are not limited thereto.
[0027] Another aspect of the present invention relates to bacteriophage MXP1002, deposited under accession number KCCM13335P, which is capable of lysing Pseudomonas aeruginosa.
[0028] Specifically, the bacteriophage MXP1002 may comprise a genome comprising a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% identity with respect to the nucleotide sequence of SEQ ID NO. 2.
[0029] Additionally, specifically, the above-mentioned Pseudomonas aeruginosa may be an antibiotic-resistant strain.
[0030] In the present invention, 'antibiotic resistance' refers to drug resistance that enables survival even when exposed to antibiotics, and includes mechanisms such as drug inactivation, alteration of target site, decreased uptake of antibiotics, efflux pump, and alteration of metabolic pathways. Genes causing such resistance or resistance to antibiotics can be transferred horizontally between strains through conjugation, transduction, or transformation. They may exhibit properties of complete resistance, partial resistance, or intermediate resistance to one or more antibiotics or antibiotic classes, and may include, for example, resistance to aztreonam, imipenem, meropenem, ceftazidim, or piperacillin / tazobactam, but are not limited thereto.
[0031] Specifically, the above 'antibiotic resistance' may include multidrug resistance. The above multidrug resistance may include resistance, partial resistance, or intermediate resistance to two or more types of antibiotics or antibiotic classes, but is not limited thereto. 'Multidrug-resistant bacteria' refers to bacteria that exhibit resistance to various types of antibiotics, and includes not only strains that acquire resistance to antibiotics due to artificial antibiotic treatment but also strains that naturally exhibit resistance to various antibiotics.
[0032] Additionally, specifically, the bacteriophage MXP1002 may enhance the susceptibility of Pseudomonas aeruginosa to antibiotics. The term 'susceptibility to antibiotics' may refer to the degree to which the survival, proliferation, replication, colonization, or biofilm formation of Pseudomonas aeruginosa is inhibited or reduced in the presence of antibiotics.
[0033] The above 'enhancement of susceptibility' may mean that the antimicrobial effect of the antibiotic against Pseudomonas aeruginosa is increased by treatment with bacteriophage MXP1002 or by the combination of bacteriophage MXP1002 and the antibiotic. For example, the above enhancement of susceptibility may be confirmed by a decrease in the minimum inhibitory concentration (MIC) of the antibiotic, a superior inhibitory or killing effect on bacterial growth when treated with the same concentration of antibiotic, a decrease in antibiotic resistance or intermediate resistance, a decrease in biofilm-forming ability, or a combination thereof, but is not limited thereto.
[0034] In one embodiment, the enhancement of susceptibility may occur by bacteriophage MXP1002 acting on Pseudomonas aeruginosa to improve access to the target site of the antibiotic, weaken the defense mechanism of Pseudomonas aeruginosa, or act complementarily or synergistically with the antibiotic, but is not limited thereto.
[0035] In addition, the above antibiotics may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but are not limited thereto.
[0036] Another aspect of the present invention relates to an antimicrobial composition comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0037] In the present invention, 'antimicrobial' refers to reducing, preventing, inhibiting, or eliminating the growth or survival of microorganisms.
[0038] In the present invention, the 'antimicrobial composition' is a composition having activity such as reducing the survival, inhibiting, or inhibiting the growth of microorganisms such as bacteria, and may collectively refer to antimicrobial agents and may include all forms used in various fields where antimicrobial effects are required. For example, it may be in the form of pharmaceuticals, quasi-pharmaceuticals, food, etc. Specifically, the antimicrobial composition of the present invention may exhibit an antimicrobial effect against antibiotic-resistant strains.
[0039] Specifically, the above antibacterial properties may be against Pseudomonas aeruginosa, but are not limited thereto.
[0040] Additionally, specifically, the antimicrobial composition may further include an antibiotic.
[0041] The above antibiotics may include, but are not limited to, carbapenem antibiotics, aminoglycoside antibiotics, cephalosporin antibiotics, tetracycline antibiotics, fluoroquinolone antibiotics, penicillin antibiotics, nitrofuran antibiotics, sulfonamide antibiotics, monobactam antibiotics, polymyxin antibiotics, or combinations thereof.
[0042] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / vaborbactam, or a combination thereof; and (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plazomicin, apramycin, or a combination thereof; (c) The above-mentioned cephalosporin antibiotic comprises cefazolin, ceftazidime, cefepime, ceftriaxone, cefiderocol, ceftazidime / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxime sodium, cefotaxime, ceftobiprole medocaril sodium, or a combination thereof; (d) The above-mentioned tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazinone, or a combination thereof;(f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / durlobactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic comprises trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0043] Another aspect of the present invention relates to a composition for inhibiting biofilm formation comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0044] In the present invention, "biofilm" may refer to a structured microbial community formed by bacteria attaching to a biological or non-biological surface and then producing extracellular polymeric substances (EPS). The biofilm may exist surrounded by a matrix containing polysaccharides, proteins, lipids, extracellular nucleic acids, etc., and accordingly may exist in a form with increased resistance to external environmental changes, host immune responses, or antimicrobial agents. Furthermore, the biofilm may be formed on the surface of a medical device, the surface of a biological tissue, a wound site, a mucosal surface, the lungs, the urinary tract, the skin, or the surface of various industrial facilities, but is not limited thereto. In one embodiment, the biofilm may be a biofilm formed by Pseudomonas aeruginosa. More specifically, the biofilm may be a biofilm formed by antibiotic-resistant Pseudomonas aeruginosa or multidrug-resistant Pseudomonas aeruginosa, but is not limited thereto.
[0045] In the present invention, "inhibition of biofilm formation" may mean inhibiting, reducing, delaying, or preventing at least one of the following stages: the initial attachment of bacteria to a surface, the formation of microcolonies, the generation of extracellular matrix to develop into a mature biofilm, or a combination thereof. The inhibition of biofilm formation may be confirmed by a decrease in the amount, thickness, density, surface coverage rate, viable cell count, or amount of extracellular matrix of the biofilm compared to a control group. Furthermore, the inhibition of biofilm formation may be a concept that includes not only the complete blockage of biofilm formation but also a significant reduction in the degree of biofilm formation, a delay in the formation rate, destabilization of the biofilm structure, or a weakening of the biofilm maintenance capacity. Accordingly, in the present invention, the term "inhibition of biofilm formation" may be used to include not only cases where biofilm formation is completely blocked but also cases where it is partially reduced or the formation efficiency is lowered.
[0046] Specifically, the biofilm may be caused by Pseudomonas aeruginosa, but is not limited thereto.
[0047] In one embodiment, the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof may inhibit the formation of a biofilm by inhibiting the proliferation of Pseudomonas aeruginosa or inhibiting initial attachment at a stage prior to biofilm formation. In another embodiment, the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof may inhibit the development of an early biofilm or an immature biofilm that has already begun to form, or hinder further maturation by reducing the stability of the biofilm structure.
[0048] Furthermore, when the above-mentioned bacteriophage MXP1001 and bacteriophage MXP1002 are used in combination or mixed, effects such as expansion of the host range, reduction of the possibility of the emergence of resistant bacteria, or improvement of biofilm inhibition efficiency may be exhibited, but are not limited thereto.
[0049] The composition for inhibiting biofilm formation of the present invention may be provided in the form of a pharmaceutical composition, a composition for a medical device, a composition for disinfection, a composition for cleaning, a composition for coating, or a composition for hygiene management. In one embodiment, the composition may be in the form of a liquid, suspension, gel, hydrogel, ointment, cream, spray, aerosol, film, patch, dressing, coating film, or lyophilized formulation, but is not limited thereto. Additionally, the composition may be used alone or may further comprise a pharmaceutically acceptable carrier, diluent, excipient, stabilizer, buffer, or preservative.
[0050] Additionally, specifically, the composition for inhibiting biofilm formation may further include an antibiotic.
[0051] The above antibiotics may include, but are not limited to, carbapenem antibiotics, aminoglycoside antibiotics, cephalosporin antibiotics, tetracycline antibiotics, fluoroquinolone antibiotics, penicillin antibiotics, nitrofuran antibiotics, sulfonamide antibiotics, monobactam antibiotics, polymyxin antibiotics.
[0052] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or a combination thereof; (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; and (c) the cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0053] When the above-mentioned bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof is used in combination with the above-mentioned antibiotic, it can inhibit the initial attachment and proliferation of bacteria in the stage prior to biofilm formation and reduce the survival rate of microorganisms inside or around the biofilm, thereby improving the accessibility or efficacy of the antibiotic. Accordingly, the composition according to the present invention can exhibit a superior biofilm formation inhibitory effect compared to antibiotic treatment alone, and can contribute to providing an enhanced antibacterial effect at the same antibiotic concentration or reducing the amount of antibiotic required. In addition, the above-mentioned composition can be usefully applied to antibiotic-resistant Pseudomonas aeruginosa or multidrug-resistant Pseudomonas aeruginosa.
[0054] Furthermore, the above-described composition for inhibiting biofilm formation can be applied not only in the medical field but also in industrial, environmental, or hygienic fields. For example, the composition can be used as a treatment agent to inhibit biofilm formation in water purification facilities, piping, storage tanks, filter systems, cooling systems, semiconductor or precision manufacturing equipment, food processing equipment, livestock or fisheries-related equipment, hospital environmental surfaces, public sanitation facilities, or other surfaces where Pseudomonas aeruginosa contamination or biofilm formation may be a problem. As such, the composition according to the present invention can be utilized not only for in vivo application but also for ex vivo surface treatment, equipment management, and hygiene management.
[0055] Furthermore, the biofilm-inhibiting composition of the present invention may be used for preventive purposes, or it may be applied preemptively in environments where a risk of infection already exists or contamination is a concern to prevent the attachment and biofilm formation of Pseudomonas aeruginosa. Additionally, by being applied at the initial contamination or initial attachment stage, it can contribute to reducing the possibility of subsequent biofilm maturation, persistent infection, bacterial persistence, or re-contamination. Therefore, the composition according to the present invention can be used as a means of prevention, management, inhibition, and auxiliary treatment in various situations where Pseudomonas aeruginosa control is required.
[0056] Another aspect of the present invention relates to a pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0057] Specifically, the bacteriophage MXP1001 or bacteriophage MXP1002 may be capable of lysing Pseudomonas aeruginosa.
[0058] In the present invention, "Pseudomonas aeruginosa infection" may refer to an infectious state resulting from Pseudomonas aeruginosa invading a host, or settling, multiplying, or surviving within or on the surface of a host. The infection may be acute or chronic, local or systemic, and may be a solitary infection or a mixed infection with other microorganisms, but is not limited thereto. Furthermore, the Pseudomonas aeruginosa infection may be an infection caused not only by antibiotic-susceptible Pseudomonas aeruginosa, but also by antibiotic-resistant Pseudomonas aeruginosa or multidrug-resistant Pseudomonas aeruginosa.
[0059] The above-mentioned Pseudomonas aeruginosa infection may occur in various parts of the body, such as the skin, mucous membranes, respiratory tract, lungs, eyes, ears, nasal cavity, oral cavity, urinary tract, genitals, gastrointestinal tract, wound site, burn site, surgical site, blood, soft tissue, bone, joint, or internal organs, but is not limited thereto. In one embodiment, the above-mentioned Pseudomonas aeruginosa infection may be pneumonia, pathogenic pneumonia, ventilator-associated pneumonia, bronchitis, chronic respiratory infection, lung infection associated with cystic fibrosis, urinary tract infection, catheter-associated infection, skin infection, soft tissue infection, wound infection, burn infection, surgical site infection, bacteremia, sepsis, otitis media, keratitis, conjunctivitis, osteomyelitis, endocarditis, or intra-abdominal infection, but is not limited thereto.
[0060] In the present invention, "disease caused by infection with Pseudomonas aeruginosa" may refer to a disease, symptom, or pathological condition that is directly or indirectly induced or aggravated by infection, colonization, proliferation, expression of toxic factors, or biofilm formation by Pseudomonas aeruginosa. The disease may include not only tissue damage caused by the proliferation of Pseudomonas aeruginosa itself, but also pathological conditions resulting from the induction of an inflammatory response, exacerbation of a host immune response, or delay or chronicity of tissue recovery. For example, the disease caused by infection with Pseudomonas aeruginosa may be one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema, but is not limited thereto.
[0061] In one embodiment, the pneumonia may be a disease caused by Pseudomonas aeruginosa infecting the lung parenchyma or lower respiratory tract, and may include hospital-acquired pneumonia, ventilator-associated pneumonia, or opportunistic pneumonia in immunocompromised patients. The lung abscess may refer to a condition in which necrosis and a pus pocket are formed within lung tissue due to Pseudomonas aeruginosa infection, and the bronchitis may refer to an inflammatory disease caused by Pseudomonas aeruginosa infection in the bronchial mucosa or lower respiratory tract. Additionally, the pleuritis or empyema may include a condition in which Pseudomonas aeruginosa infection extends into the pleural cavity, causing inflammation of the pleura or accumulation of pus.
[0062] In addition, the above meningitis may refer to an inflammatory disease caused by Pseudomonas aeruginosa infecting the meninges or the central nervous system, and the above endocarditis may refer to a disease caused by Pseudomonas aeruginosa infecting the endocardium or heart valves. The above bacteremia may refer to a state in which Pseudomonas aeruginosa is present in the bloodstream, and the above sepsis may include a state accompanied by a host systemic inflammatory response to such infection or organ dysfunction. Accordingly, bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof according to the present invention can be usefully applied to the prevention or treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection occurring in various parts such as the respiratory system, circulatory system, or central nervous system.
[0063] Furthermore, diseases caused by the above-mentioned Pseudomonas aeruginosa infection are not limited to the diseases exemplified above and may include other local or systemic diseases that may be caused or aggravated by infection or proliferation of Pseudomonas aeruginosa. For example, diseases caused by the above-mentioned Pseudomonas aeruginosa infection may additionally include, but are not limited to, urinary tract infections, catheter-associated infections, skin infections, soft tissue infections, wound infections, burn infections, surgical site infections, keratitis, conjunctivitis, otitis media, osteomyelitis, or intra-abdominal infections.
[0064] Additionally, specifically, the above-mentioned Pseudomonas aeruginosa may be an antibiotic-resistant Pseudomonas aeruginosa. The above-mentioned "antibiotic resistance" may refer to a property of exhibiting complete resistance, partial resistance, or intermediate resistance to one or more antibiotics or antibiotic classes. For example, it may include, but is not limited to, resistance to aztreonam, imipenem, meropenem, ceftazidim, or piperacillin / tazobactam.
[0065] Specifically, the above 'antibiotic resistance' may include multidrug resistance. The above multidrug resistance may include resistance, partial resistance, or intermediate resistance to two or more antibiotics or antibiotic classes, but is not limited thereto.
[0066] Also specifically, the total dose of bacteriophages included in the above pharmaceutical composition is 1 x 10 2 PFU / mL to 1X10 15 It may be PFU / mL, but is not limited thereto.
[0067] For example, the above total bacteriophage concentration is approximately 1×10² PFU / mL, 2×10² PFU / mL, 3×10² PFU / mL, 4×10² PFU / mL, 5×10² PFU / mL, 6×10² PFU / mL, 7×10 2 PFU / mL, 8Х10² PFU / mL, 9Х10² PFU / mL, 1Х10³ PFU / mL, 2Х10³ PFU / mL, 3Х10 3 PFU / mL, 4Х10³ PFU / mL, 5Х10³ PFU / mL, 6Х10³ PFU / mL, 7Х10³ PFU / mL, 8Х10 3 PFU / mL, 9×10³ PFU / mL, 1×10⁻⁶ 4 PFU / mL, 2Х10⁴ PFU / mL, 3Х10⁴ PFU / mL, 4Х10⁴ PFU / mL, 5Х10⁴ PFU / mL, 6Х10⁴ PFU / mL, 7Х10⁴ PFU / mL, 8Х10⁴ PFU / mL, 9Х10 4 PFU / mL, 1X10 5 PFU / mL, 2X105 PFU / mL, 3Х10 5 PFU / mL, 4Х10 5 PFU / mL, 5Х10 5 PFU / mL, 6Х10 5 PFU / mL, 7Х10 5 PFU / mL, 8Х10 5 PFU / mL, 9Х10 5 PFU / mL, 1Х10 6 PFU / mL, 2Х10 6 PFU / mL, 3Х10 6 PFU / mL, 4Х10 6 PFU / mL, 5Х10 6 PFU / mL, 6Х10 6 PFU / mL, 7Х10 6 PFU / mL, 8Х10 6 PFU / mL, 9Х10 6 PFU / mL, 1Х10 7 PFU / mL, 2Х10 7 PFU / mL, 3Х10 7 PFU / mL, 4Х10 7 PFU / mL, 5Х10 7 PFU / mL, 6Х10 7 PFU / mL, 7Х10 7 PFU / mL, 8Х10 7 PFU / mL, 9Х10 7 PFU / mL, 1Х10 8 PFU / mL, 2Х10 8 PFU / mL, 3Х10 8 PFU / mL, 4Х10 8 PFU / mL, 5Х10 8 PFU / mL, 6Х10 8 PFU / mL, 7Х10 8 PFU / mL, 8Х10 8 PFU / mL, 9Х10 8 PFU / mL, 1Х10 9 PFU / mL, 2Х10 9 PFU / mL, 3Х10 9 PFU / mL, 4Х10 9 PFU / mL, 5Х10 9 PFU / mL, 6Х109 PFU / mL, 7Х10 9 PFU / mL, 8Х10 9 PFU / mL, 9Х10 9 PFU / mL, 1Х10 10 PFU / mL, 2Х10 10 PFU / mL, 3Х10 10 PFU / mL, 4Х10 10 PFU / mL, 5Х10 10 PFU / mL, 6Х10 10 PFU / mL, 7Х10 10 PFU / mL, 8Х10 10 PFU / mL, 9Х10 10 PFU / mL, 1Х10 11 PFU / mL, 2Х10 11 PFU / mL, 3Х10 11 PFU / mL, 4Х10 11 PFU / mL, 5Х10 11 PFU / mL, 6Х10 11 PFU / mL, 7Х10 11 PFU / mL, 8Х10 11 PFU / mL, 9Х10 11 PFU / mL, 1Х10 12 PFU / mL, 2Х10 12 PFU / mL, 3Х10 12 PFU / mL, 4Х10 12 PFU / mL, 5Х10 12 PFU / mL, 6Х10 12 PFU / mL, 7Х10 12 PFU / mL, 8Х10 12 PFU / mL, 9Х10 12 PFU / mL, 1Х10 13 PFU / mL, 2Х10 13 PFU / mL, 3Х10 13 PFU / mL, 4Х10 13 PFU / mL, 5Х10 13 PFU / mL, 6Х10 13 PFU / mL, 7Х10 13 PFU / mL, 8Х10 13 PFU / mL, 9Х10 13 PFU / mL, 1Х1014 PFU / mL, 2X10 14 PFU / mL, 3X10 14 PFU / mL, 4X10 14 PFU / mL, 5X10 14 PFU / mL, 6X10 14 PFU / mL, 7X10 14 PFU / mL, 8X10 14 PFU / mL, 9X10 14 PFU / mL or 1×10⁻⁶ 15 It can be PFU / mL.
[0068] In the present invention, 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage included in the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof included in the pharmaceutical composition. For example, if the composition includes only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if the composition includes both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0069] In the present invention, when bacteriophage MXP1001 and bacteriophage MXP1002 are included together, bacteriophage MXP1001 and bacteriophage MXP1002 may be included at the same or substantially the same potency.
[0070] In one embodiment, the respective titers of the first bacteriophage and the second bacteriophage mixed may differ from each other by less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1%. In another embodiment, the first bacteriophage and the second bacteriophage may be included in a titer ratio of about 1:1.
[0071] Additionally, the first bacteriophage and the second bacteriophage may be included at a titer ratio of about 1.01:1, about 1.02:1, about 1.03:1, about 1.04:1, about 1.05:1, about 1.06:1, about 1.07:1, about 1.08:1, about 1.09:1 or about 1.1:1, or may be included at a titer ratio of about 1:1.01, about 1:1.02, about 1:1.03, about 1:1.04, about 1:1.05, about 1:1.06, about 1:1.07, about 1:1.08, about 1:1.09 or about 1:1.1. In another embodiment, the first bacteriophage and the second bacteriophage may be included at a potency ratio of about 2:1 or less, for example, about 1.2:1, about 1.3:1, about 1.4:1, about 1.5:1, about 1.6:1, about 1.7:1, about 1.8:1, about 1.9:1 or about 2:1, or may be included at a potency ratio of about 1:2 or less, for example, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, about 1:1.9 or about 1:2.
[0072] In another embodiment, the first bacteriophage and the second bacteriophage may be included in a titer ratio of about 3:1 or less or about 1:3 or less, for example, about 2.1:1, about 2.2:1, about 2.3:1, about 2.4:1, about 2.5:1, about 2.6:1, about 2.7:1, about 2.8:1, about 2.9:1, about 3:1, about 1:2.1, about 1:2.2, about 1:2.3, about 1:2.4, about 1:2.5, about 1:2.6, about 1:2.7, about 1:2.8, about 1:2.9 or about 1:3.
[0073] The total dose of bacteriophage described above may be appropriately adjusted according to the target, site of infection, degree of infection, route of administration, formulation, frequency of administration, presence or absence of concomitant drugs, or desired effect. Additionally, the dose range may be interpreted as a single dose, a dose per formulation, a daily dose, or a dose over the entire course of treatment, and may vary depending on the specific method of application, but is not limited thereto. In one embodiment, the total dose of bacteriophage may be an amount effective for effectively lysing Pseudomonas aeruginosa, inhibiting the proliferation, colonization, or biofilm formation of Pseudomonas aeruginosa, or for preventing or treating Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection.
[0074] Additionally, specifically, the above composition may further include an antibiotic.
[0075] The above antibiotics may include, but are not limited to, carbapenem antibiotics, aminoglycoside antibiotics, cephalosporin antibiotics, tetracycline antibiotics, fluoroquinolone antibiotics, penicillin antibiotics, nitrofuran antibiotics, sulfonamide antibiotics, monobactam antibiotics, polymyxin antibiotics.
[0076] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or a combination thereof; (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; and (c) the cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0077] Bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof included in the pharmaceutical composition of the present invention, when used in combination with the antibiotic, can reduce the number of Pseudomonas aeruginosa, inhibit or destabilize biofilm formation, and improve the accessibility or efficacy of the antibiotic. Furthermore, the bacteriophage can enhance the susceptibility of Pseudomonas aeruginosa to antibiotics, thereby contributing to providing an improved antimicrobial effect compared to antibiotic treatment alone or reducing the amount of antibiotic required. Additionally, the composition may exhibit preventive or therapeutic effects against antibiotic-resistant Pseudomonas aeruginosa or multidrug-resistant Pseudomonas aeruginosa, but is not limited thereto.
[0078] In the present invention, "prevention" may mean preventing Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, or reducing the likelihood, frequency, severity, or recurrence of such occurrence. Such prevention may include inhibiting the attachment, colonization, proliferation, or biofilm formation of Pseudomonas aeruginosa at a stage prior to infection, and may include, but is not limited to, cases where it is applied preemptively to high-risk groups or sites of concern for infection. Furthermore, such prevention may be used to mean not only complete blockage of infection, but also delaying infection, mitigating the severity of infection, or reducing the risk of complications arising from infection.
[0079] In the present invention, "treatment" may mean improving, alleviating, suppressing, reducing, or delaying the cause, symptoms, progression, or recurrence of an existing Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection. The treatment may include inhibiting the survival or proliferation of Pseudomonas aeruginosa, reducing the number of bacteria by lysing Pseudomonas aeruginosa, inhibiting or destabilizing biofilms, or alleviating inflammatory responses or tissue damage associated with the infection. Furthermore, the treatment may be used to mean not only complete healing but also partial improvement of symptoms, reduction of the rate of disease progression, reduction of the scope of infection, suppression of recurrence, or improvement of prognosis, but is not limited thereto.
[0080] In the present invention, the pharmaceutical composition may be administered orally or parenterally. Oral administration may be in the form of tablets, capsules, granules, powders, liquids, suspensions, or syrups, but is not limited thereto. Additionally, parenteral administration may be subcutaneously, intradermally, intravenously, intra-arterially, intramuscularly, intraperitoneally, intra-abdominally, intrathecally, intrathecally, intrathecally, or rectally, but is not limited thereto. In one embodiment, the pharmaceutical composition may be administered via an appropriate route of administration selected according to the site of infection, the severity of the infection, the condition of the subject, the purpose of administration, or the characteristics of the formulation. Additionally, the pharmaceutical composition may be administered as a single dose or multiple times, and may be administered repeatedly for a certain period as necessary.
[0081] The pharmaceutical composition of the present invention may be applied in a pharmaceutically effective amount, and a "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the patient's gender, age, type and severity of the disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0082] Another aspect of the present invention relates to a kit for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof; and instructions.
[0083] In the present invention, the term "kit" may refer to a product, package, combination, or system configured to conveniently use bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof for the prevention or treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection. The kit may contain the bacteriophage alone or may contain two or more types of bacteriophages together, and may include additional components as needed, but is not limited thereto.
[0084] In one embodiment, the kit may comprise one or more containers, packaging materials, or storage means comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof. The container may be a vial, ampoule, syringe, cartridge, tube, pouch, bottle, bag, or other suitable receiving means, and the bacteriophage may be provided in liquid, lyophilized, powder, suspension, or gel form, but is not limited thereto. Additionally, the kit may further comprise a buffer, diluent, reconstitution solution, stabilizer, preservative, refrigerant, or sealing packaging material to maintain the stability, transport, or ease of use of the bacteriophage.
[0085] The above "instructions" may refer to printed materials, labels, package inserts, electronic documents, electronic media, or a combination thereof that provide information regarding the use, method of use, route of administration, dosage, storage conditions, handling method, precautions, target subjects, or concomitant ingredients of bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof included in the kit. The above instructions may state the purpose of use for the prevention or treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, and may include, but are not limited to, the fact that the bacteriophage may lyse Pseudomonas aeruginosa, inhibit the proliferation or biofilm formation of Pseudomonas aeruginosa, or enhance susceptibility to antibiotics.
[0086] The kit according to the present invention is approximately 1 x 10² PFU / mL to approximately 1 x 10 based on total bacteriophage concentration 15 It may contain bacteriophages in PFU / mL, but is not limited thereto. For example, the kit contains about 1X10² to about 1X10³ PFU / mL based on total bacteriophage concentration, about 1X10³ to about 1X10 4 PFU / mL, approx. 1X10 4 to about 1 x 10 5 PFU / mL, approx. 1X10 5 to about 1 x 10 6 PFU / mL, approx. 1X10 6 to about 1 x 10 7 PFU / mL, approx. 1X10 7 to about 1 x 10 8 PFU / mL, approx. 1X10 8 to about 1 x 10 9 PFU / mL, approx. 1X10 9 to about 1 x 10 10 PFU / mL, approx. 1X10 10 to about 1 x 10 11 PFU / mL, approx. 1X10 11 to about 1 x 10 12PFU / mL, approx. 1X10 12 to about 1 x 10 13 PFU / mL, approx. 1X10 13 to about 1 x 10 14 PFU / mL, or about 1 x 10⁻⁶ 14 to about 1 x 10 14 It may contain bacteriophages at a PFU / mL concentration. In one embodiment, the kit is approximately 9×10 based on the total bacteriophage concentration. 6 to about 2x10 7 PFU / mL, e.g., about 1 x 10⁻⁶ 7 It may contain bacteriophages at a PFU / mL concentration. In another embodiment, the kit is approximately 9×10 based on the total bacteriophage concentration. 8 to about 2x10 9 PFU / mL, e.g., about 1 x 10⁻⁶ 9 It may contain bacteriophages at a PFU / mL concentration. In another embodiment, the kit is approximately 9×10 based on the total bacteriophage concentration. 10 to about 2x10 11 PFU / mL, e.g., about 1 x 10⁻⁶ 11 It may contain bacteriophages of PFU / mL.
[0087] In one embodiment, the kit may include a first bacteriophage deposited in a first container under accession number KCCM13247P and a second bacteriophage deposited in a second container under accession number KCCM13335P, and may be included in the opposite way.
[0088] Specifically, the above kit may additionally include antibiotics.
[0089] The above antibiotics may include, but are not limited to, carbapenem antibiotics, aminoglycoside antibiotics, cephalosporin antibiotics, tetracycline antibiotics, fluoroquinolone antibiotics, penicillin antibiotics, nitrofuran antibiotics, sulfonamide antibiotics, monobactam antibiotics, polymyxin antibiotics.
[0090] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or a combination thereof; (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; and (c) the cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0091] Additionally, the kit may be provided in a configuration for injectable, oral, topical application, inhalation, ophthalmic, diaphoretic, dressing, coating, or medical device application, depending on the convenience of administration or the purpose of use. For example, the kit may be composed of a combination of a syringe and a vial, a combination of a lyophilized vial and a reconstituted solution, a combination of a dressing or patch and a bacteriophage formulation, or a combination of a nebulizer and a liquid composition, but is not limited thereto.
[0092] In addition, the kit may be used on subjects at risk of Pseudomonas aeruginosa infection, subjects suspected or confirmed to have an infection caused by antibiotic-resistant or multidrug-resistant Pseudomonas aeruginosa, or in wounds, burns, surgical sites, respiratory or urinary tracts, or medical device application environments where attachment or biofilm formation by Pseudomonas aeruginosa is a concern. The kit may be useful for the prevention, treatment, suppression of recurrence, or infection control of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, but is not limited thereto.
[0093] Another aspect of the present invention relates to a food composition for the prevention or improvement of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
[0094] In the present invention, the term "food composition" may refer to a composition that can be provided in the form of a food, health functional food, food for special medical purposes, nutritional supplement, beverage, liquid composition, powder composition, granular composition, tablet, capsule, jelly, gel, bar, concentrate, or a combination thereof, which can be consumed by humans or animals, but is not limited thereto. The food composition may help inhibit the proliferation, colonization, or biofilm formation of Pseudomonas aeruginosa by including bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof as an active ingredient, and help reduce the likelihood of Pseudomonas aeruginosa infection or the likelihood of disease caused by Pseudomonas aeruginosa infection or exacerbation thereof.
[0095] In the present invention, 'prevention or improvement' may mean preventing the occurrence of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, reducing the likelihood, frequency, severity, or recurrence of such occurrence, or alleviating, reducing, improving, or preventing the worsening of existing Pseudomonas aeruginosa-related symptoms, conditions, or pathological states. The term 'improvement' is not limited to meaning complete cure and may be used to include a reduction in the number of Pseudomonas aeruginosa bacteria, inhibition of colonization, inhibition of biofilm formation, alleviation of the infection environment, reduction of inflammatory conditions, or reduction of the risk of recurrence.
[0096] Specifically, the bacteriophage MXP1001 or bacteriophage MXP1002 can enhance the susceptibility of Pseudomonas aeruginosa to antibiotics.
[0097] "Enhanced susceptibility to antibiotics" may refer to a state in which Pseudomonas aeruginosa becomes more sensitive to one or more antibiotics, so that survival, proliferation, colonization, or biofilm formation is more effectively inhibited by antibiotics at the same or lower concentrations. This enhanced susceptibility may be confirmed by, but is not limited to, a decrease in the minimum inhibitory concentration (MIC) of the antibiotic, a decrease in the minimum bactericidal concentration (MBC), an increase in the reduction of viable bacteria, an increase in bacterial growth inhibition, a decrease in the amount of biofilm formed, a decrease in the number of viable bacteria within the biofilm, or an improvement in antibiotic treatment efficiency.
[0098] Bacteriophage MXP1001 or bacteriophage MXP1002 can create an environment in which antibiotics can act more effectively on Pseudomonas aeruginosa by directly lysing Pseudomonas aeruginosa, affecting the structure of the bacterial cell wall or cell membrane, altering the physiological state of the bacteria, or inhibiting or destabilizing biofilm formation. In addition, the bacteriophage can enhance antibiotic susceptibility by reducing the density of the Pseudomonas aeruginosa population, improving the penetration or accessibility of antibiotics, and weakening the biological state involved in the development or maintenance of resistance to antibiotics, but is not limited thereto.
[0099] In one embodiment, the enhancement of susceptibility may occur by bacteriophage MXP1001 acting on Pseudomonas aeruginosa to improve access to the target site of the antibiotic, weaken the defense mechanism of Pseudomonas aeruginosa, or act complementarily or synergistically with the antibiotic, but is not limited thereto.
[0100] In addition, the above antibiotics may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but are not limited thereto.
[0101] In the present invention, the disease caused by Pseudomonas aeruginosa infection may refer to a disease, symptom, or pathological condition that occurs or is exacerbated directly or indirectly by the invasion, colonization, proliferation, expression of toxic factors, induction of inflammation, or biofilm formation of Pseudomonas aeruginosa. The disease may appear confined to a single organ or tissue, or may progress systemically through diffusion into the bloodstream or adjacent tissues, and may appear in an acute or chronic form, but is not limited thereto. For example, the disease caused by Pseudomonas aeruginosa infection may be one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema, but is not limited thereto.
[0102] Furthermore, diseases caused by the above-mentioned Pseudomonas aeruginosa infection are not limited to the diseases exemplified above and may include other local or systemic diseases that may be caused or aggravated by infection or proliferation of Pseudomonas aeruginosa. For example, diseases caused by the above-mentioned Pseudomonas aeruginosa infection may additionally include, but are not limited to, urinary tract infections, catheter-associated infections, skin infections, soft tissue infections, wound infections, burn infections, surgical site infections, keratitis, conjunctivitis, otitis media, osteomyelitis, or intra-abdominal infections.
[0103] Also specifically, the total bacteriophage dose included in the food composition is 1 x 10 2 PFU to 1X10 15It may be a PFU, but is not limited to this.
[0104] In the present invention, 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage included in the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof included in the food composition. For example, if the food composition includes only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if it includes both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0105] The total bacteriophage dose may be appropriately adjusted according to the formulation of the food composition, the target of consumption, the frequency of consumption, the purpose of application, or the expected effect. Additionally, the dose range may be interpreted as the amount included per single serving, per daily serving, or per unit of the final product, and may vary depending on the specific method of application, but is not limited thereto. In one embodiment, the total bacteriophage dose may be an amount effective for inhibiting the proliferation, colonization, or biofilm formation of Pseudomonas aeruginosa, and for reducing the likelihood of Pseudomonas aeruginosa infection or the likelihood of disease caused by Pseudomonas aeruginosa infection.
[0106] In addition, in one embodiment, the food composition may be provided in the form of a powder, granule, tablet, capsule, liquid beverage, fermented milk, jelly, gel, bar, pill, or concentrate, but is not limited thereto. In addition, the food composition may further include a food-acceptable carrier, diluent, excipient, stabilizer, pH adjuster, coating agent, or protective agent to maintain the stability or viability of the bacteriophage.
[0107] In addition, the above food composition may be consumed alone, and may additionally include probiotics, prebiotics, postbiotics, vitamins, minerals, amino acids, peptides, dietary fiber, plant extracts, or other functional food materials. These additional ingredients may be included for the purpose of regulating the intestinal or internal environment, supplementing the nutritional status of the subject, or assisting the action of the bacteriophage according to the present invention, but are not limited thereto.
[0108] In one embodiment, the food composition may be applied to subjects at risk of Pseudomonas aeruginosa infection, subjects with compromised immunity, long-term hospitalized patients, patients with implanted medical devices, patients with chronic wounds or burns, subjects at risk of recurrent respiratory or urinary tract infections, or subjects at high risk of exposure to antibiotic-resistant Pseudomonas aeruginosa. Additionally, the food composition may be consumed in an environment where colonization or proliferation of Pseudomonas aeruginosa is a concern, thereby helping to reduce the likelihood of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, or to help improve related conditions.
[0109] In addition, the food composition according to the present invention is not limited to medicinal uses intended for the direct treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, but can be usefully used to lower Pseudomonas aeruginosa-related risks through daily consumption and to help improve abnormal conditions or symptoms caused by Pseudomonas aeruginosa.
[0110] Another aspect of the present invention relates to a method for preventing, treating, or improving a Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual.
[0111] The above bacteriophage MXP1001 may include a genome comprising a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% identity with respect to the nucleotide sequence of SEQ ID NO. 1.
[0112] The above bacteriophage MXP1002 may include a genome comprising a nucleotide sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% identity with respect to the nucleotide sequence of SEQ ID NO. 2.
[0113] In the present invention, 'individual' may refer to a human or non-human animal capable of obtaining a preventive or therapeutic effect against Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection by administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof according to the present invention, or a pharmaceutical composition containing the same. The non-human animal may include mammals, birds, reptiles, amphibians, or fish, and more specifically may be a mouse, rat, rabbit, dog, cat, cattle, horse, pig, sheep, goat, or monkey, but is not limited thereto. In one embodiment, the individual may be an individual suspected or confirmed to have Pseudomonas aeruginosa infection, an individual at high risk of developing disease caused by Pseudomonas aeruginosa infection, an individual exposed to or infected with antibiotic-resistant Pseudomonas aeruginosa or multidrug-resistant Pseudomonas aeruginosa, or an individual of concern regarding colonization or biofilm formation by Pseudomonas aeruginosa.
[0114] In the present invention, 'Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection' is as described above and may include, for example, pneumonia, lung abscess, bronchitis, pleurisy, empyema, meningitis, endocarditis, bacteremia, sepsis, urinary tract infection, skin infection, soft tissue infection, wound infection, burn infection, surgical site infection, keratitis, conjunctivitis, otitis media, osteomyelitis, catheter-associated infection or medical device-associated infection, but is not limited thereto.
[0115] The method according to the present invention can effectively prevent or treat Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection by administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual, thereby inhibiting the proliferation, colonization, or survival of Pseudomonas aeruginosa, reducing the number of bacteria by lysing Pseudomonas aeruginosa, or inhibiting or destabilizing the formation of biofilms by Pseudomonas aeruginosa. In addition, the method may be useful for reducing the likelihood, frequency, severity, duration, or recurrence of infection.
[0116] In the present invention, "administration" may mean introducing a pharmaceutical composition according to the present invention to a human or animal by any appropriate method. The bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof, or a pharmaceutical composition containing the same, may be administered via various routes including oral or parenteral, as long as they can reach the target tissue or the site of infection. For example, the pharmaceutical composition may be administered in the form of oral administration, parenteral administration, topical administration, inhalation administration, nebulization administration, ophthalmic administration, nasal drop administration, ear administration, rectal administration, or application of a medical device, but is not limited thereto. Additionally, the parenteral administration may be subcutaneous, intradermal, intravenous, arterial, intramuscular, abdominal cavity, dura mater, joint, synovial sac, sternum, lesion, or rectal administration, but is not limited thereto.
[0117] Bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof according to the present invention, and a pharmaceutical composition comprising the same may be formulated for oral, subcutaneous, intradermal, intravenous, arterial, muscular, abdominal cavity, dura mater, joint, synovial bursa, sternum, lesion, or rectal administration.
[0118] Furthermore, the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof according to the present invention, and a pharmaceutical composition comprising the same may be administered through any suitable device capable of delivering the active ingredient to a target cell or target site, such as a syringe, catheter, nebulizer, spray device, dropper, dressing, patch, or coated medical device.
[0119] In the method according to the present invention, the timing, frequency, interval, duration, and dosage of administration of bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof, or a pharmaceutical composition containing the same, may be appropriately adjusted according to the individual's condition, age, body weight, site of infection, severity of infection, type of disease, characteristics of the formulation, presence or absence of concomitant drugs, or expected therapeutic effect. The effective dosage of the pharmaceutical composition according to the present invention may be appropriately selected by a person skilled in the art and may be provided in the form of a single administration or multiple administrations. Furthermore, the administration may be in the form of continuous, intermittent, repetitive, or as needed, but is not limited thereto.
[0120] In one embodiment, the method according to the present invention may include the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof, or a pharmaceutical composition containing the same, alone.
[0121] In another embodiment, the method may further include the step of administering the bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof, a pharmaceutical composition containing the same, and an antibiotic in combination.
[0122] In addition, in another embodiment of the present invention, the method may include combination therapy with an antibiotic. The antibiotic may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but is not limited thereto.
[0123] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or a combination thereof; (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; and (c) the cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0124] In the above combination therapy, the pharmaceutical composition according to the present invention and the antibiotic may be administered simultaneously, sequentially, or separately. For example, the pharmaceutical composition containing the bacteriophage may be administered first followed by the antibiotic, the antibiotic may be administered first followed by the pharmaceutical composition, or both may be administered substantially simultaneously. Additionally, the bacteriophage and the antibiotic may be administered together within the same formulation or composition, or they may be manufactured into separate formulations and administered independently.
[0125] The combination therapy according to the present invention can exhibit an enhanced preventive or therapeutic effect compared to the administration of an antibiotic alone by reducing the number of Pseudomonas aeruginosa bacteria, inhibiting or destabilizing biofilm formation, and improving the accessibility of the antibiotic to the infection site or the efficiency of action. In addition, the combination therapy may contribute to enhancing the susceptibility of Pseudomonas aeruginosa to antibiotics, achieving the same effect at lower antibiotic concentrations, reducing the amount of antibiotics required, or improving the therapeutic responsiveness against antibiotic-resistant or multidrug-resistant Pseudomonas aeruginosa, but is not limited thereto.
[0126] Also specifically, the total dose of bacteriophage administered to the said individual is 1 x 10 2 PFU / mL to 1X10 15 It may be PFU / mL, but is not limited thereto.
[0127] In the present invention, 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage contained in the administered bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof. For example, if the composition contains only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if it contains both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0128] For example, the total bacteriophage concentration is approximately 1 x 10⁻⁶ 2 PFU / mL, 2X10 2 PFU / mL, 3X10 2 PFU / mL, 4X10 2 PFU / mL, 5X10 2 PFU / mL, 6X10 2 PFU / mL, 7X10 2 PFU / mL, 8X10 2 PFU / mL, 9X10 2 PFU / mL, 1X10 3 PFU / mL, 2X10 3 PFU / mL, 3X10 3 PFU / mL, 4X10 3 PFU / mL, 5X10 3 PFU / mL, 6X10 3 PFU / mL, 7X10 3 PFU / mL, 8X10 3 PFU / mL, 9X10 3 PFU / mL, 1X10 4 PFU / mL, 2X10 4 PFU / mL, 3X10 4 PFU / mL, 4X10 4 PFU / mL, 5X10 4 PFU / mL, 6X10 4 PFU / mL, 7X10 4 PFU / mL, 8X10 4 PFU / mL, 9X10 4 PFU / mL, 1X105 PFU / mL, 2Х10 5 PFU / mL, 3Х10 5 PFU / mL, 4Х10 5 PFU / mL, 5Х10 5 PFU / mL, 6Х10 5 PFU / mL, 7Х10 5 PFU / mL, 8Х10 5 PFU / mL, 9Х10 5 PFU / mL, 1Х10 6 PFU / mL, 2Х10 6 PFU / mL, 3Х10 6 PFU / mL, 4Х10 6 PFU / mL, 5Х10 6 PFU / mL, 6Х10 6 PFU / mL, 7Х10 6 PFU / mL, 8Х10 6 PFU / mL, 9Х10 6 PFU / mL, 1Х10 7 PFU / mL, 2Х10 7 PFU / mL, 3Х10 7 PFU / mL, 4Х10 7 PFU / mL, 5Х10 7 PFU / mL, 6Х10 7 PFU / mL, 7Х10 7 PFU / mL, 8Х10 7 PFU / mL, 9Х10 7 PFU / mL, 1Х10 8 PFU / mL, 2Х10 8 PFU / mL, 3Х10 8 PFU / mL, 4Х10 8 PFU / mL, 5Х10 8 PFU / mL, 6Х10 8 PFU / mL, 7Х10 8 PFU / mL, 8Х10 8 PFU / mL, 9Х10 8 PFU / mL, 1Х10 9 PFU / mL, 2Х10 9 PFU / mL, 3Х10 9 PFU / mL, 4Х10 9 PFU / mL, 5Х109 PFU / mL, 6Х10 9 PFU / mL, 7Х10 9 PFU / mL, 8Х10 9 PFU / mL, 9Х10 9 PFU / mL, 1Х10 10 PFU / mL, 2Х10 10 PFU / mL, 3Х10 10 PFU / mL, 4Х10 10 PFU / mL, 5Х10 10 PFU / mL, 6Х10 10 PFU / mL, 7Х10 10 PFU / mL, 8Х10 10 PFU / mL, 9Х10 10 PFU / mL, 1Х10 11 PFU / mL, 2Х10 11 PFU / mL, 3Х10 11 PFU / mL, 4Х10 11 PFU / mL, 5Х10 11 PFU / mL, 6Х10 11 PFU / mL, 7Х10 11 PFU / mL, 8Х10 11 PFU / mL, 9Х10 11 PFU / mL, 1Х10 12 PFU / mL, 2Х10 12 PFU / mL, 3Х10 12 PFU / mL, 4Х10 12 PFU / mL, 5Х10 12 PFU / mL, 6Х10 12 PFU / mL, 7Х10 12 PFU / mL, 8Х10 12 PFU / mL, 9Х10 12 PFU / mL, 1Х10 13 PFU / mL, 2Х10 13 PFU / mL, 3Х10 13 PFU / mL, 4Х10 13 PFU / mL, 5Х10 13 PFU / mL, 6Х10 13 PFU / mL, 7Х10 13 PFU / mL, 8Х10 13 PFU / mL, 9Х1013 PFU / mL, 1X10 14 PFU / mL, 2X10 14 PFU / mL, 3X10 14 PFU / mL, 4X10 14 PFU / mL, 5X10 14 PFU / mL, 6X10 14 PFU / mL, 7X10 14 PFU / mL, 8X10 14 PFU / mL, 9X10 14 PFU / mL or 1×10⁻⁶ 15 It can be PFU / mL.
[0129] When the above bacteriophage MXP1001 and bacteriophage MXP1002 are included together, bacteriophage MXP1001 and bacteriophage MXP1002 may be included at the same or substantially the same potency.
[0130] Another aspect of the present invention relates to a method for enhancing antibiotic susceptibility of Pseudomonas aeruginosa, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual that has a Pseudomonas aeruginosa infection or is at risk of Pseudomonas aeruginosa infection.
[0131] Specifically, the above method may include a step of administering in combination with an antibiotic.
[0132] The above antibiotics may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but are not limited thereto.
[0133] Also specifically, the total dose of bacteriophage administered to the said individual is 1 x 10 2 PFU / mL to 1X10 15It may be PFU / mL, but is not limited thereto.
[0134] The above 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage contained in the administered bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof. For example, if the composition contains only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if it contains both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0135] When the above bacteriophage MXP1001 and bacteriophage MXP1002 are included together, bacteriophage MXP1001 and bacteriophage MXP1002 may be included at the same or substantially the same potency.
[0136] Another aspect of the present invention relates to a method for inhibiting or reducing a Pseudomonas aeruginosa biofilm, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to a site where a Pseudomonas aeruginosa biofilm has been formed or is at risk of being formed.
[0137] Specifically, the above method may include a step of administering in combination with an antibiotic.
[0138] The above antibiotics may include carbapenem, aminoglycoside, cephalosporin, tetracycline, fluoroquinolone, penicillin, nitrofuran, sulfonamide, monobactam, or polymyxin antibiotics, and may be, for example, amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, levofloxacin, colistin, or a combination thereof, but are not limited thereto.
[0139] Also specifically, the dose of the total bacteriophage administered is 1 x 10⁻¹⁰ 2PFU / mL to 1X10 15 It may be PFU / mL, but is not limited thereto.
[0140] The above 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage contained in the administered bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof. For example, if the composition contains only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if it contains both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0141] When the above bacteriophage MXP1001 and bacteriophage MXP1002 are included together, bacteriophage MXP1001 and bacteriophage MXP1002 may be included at the same or substantially the same potency.
[0142] Another aspect of the present invention relates to the use of bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof capable of lysing Pseudomonas aeruginosa for the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection.
[0143] Specifically, the above antibiotic may be additionally included.
[0144] The above antibiotics may include, but are not limited to, carbapenem antibiotics, aminoglycoside antibiotics, cephalosporin antibiotics, tetracycline antibiotics, fluoroquinolone antibiotics, penicillin antibiotics, nitrofuran antibiotics, sulfonamide antibiotics, monobactam antibiotics, polymyxin antibiotics.
[0145] More specifically, (a) the carbapenem antibiotic comprises doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or a combination thereof; (b) the aminoglycoside antibiotic comprises amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; and (c) the cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotetan, cefoxitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The nitrofuran antibiotic comprises nitrofurantoin; (h) The sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) The polymyxin antibiotic may comprise colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof, but is not limited thereto.
[0146] Also specifically, the dose of the total bacteriophage administered is 1 x 10⁻¹⁰ 2 PFU / mL to 1X10 15It may be PFU / mL, but is not limited thereto.
[0147] The above 'total bacteriophage dose' may refer to the potency or amount of the total bacteriophage contained in the administered bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof. For example, if the composition contains only bacteriophage MXP1001, the total bacteriophage dose may be the dose of MXP1001, and if it contains both bacteriophage MXP1001 and bacteriophage MXP1002, the total bacteriophage dose may be the sum of the doses of MXP1001 and MXP1002.
[0148] When the above bacteriophage MXP1001 and bacteriophage MXP1002 are included together, bacteriophage MXP1001 and bacteriophage MXP1002 may be included at the same or substantially the same potency.
[0149] The bacteriophage of the present invention or a composition containing the same can selectively lyse Pseudomonas aeruginosa and inhibit the proliferation or replication of Pseudomonas aeruginosa, and can be usefully used to treat, prevent, or improve Pseudomonas aeruginosa infection or diseases, disorders, or conditions associated with Pseudomonas aeruginosa infection, and can exhibit excellent antimicrobial activity against various clinical isolates of Pseudomonas aeruginosa, and can contribute to reducing the metabolic activity of biofilms and inhibiting biofilms.
[0150] In addition, the combination of one or more bacteriophages and one or more antibiotics of the present invention can be effectively used as a combination therapy to treat and / or prevent Pseudomonas aeruginosa infection or diseases, disorders, or conditions associated with Pseudomonas aeruginosa infection in subjects.
[0151] The combination of one or more bacteriophages and one or more antibiotics of the present invention may exhibit a synergistic antimicrobial effect when administered in combination. This synergistic effect may result from interactions between bacteriophages and antibiotics utilizing mutually complementary and different mechanisms of action. For example, antibiotics may promote the adsorption and proliferation of bacteriophages, and bacteriophages may expose the target sites of antibiotics.
[0152] The combination of one or more bacteriophages and one or more antibiotics of the present invention can make it difficult for bacteria to survive and adapt by causing them to respond to two antimicrobial actions simultaneously. For example, simultaneous adaptation to both bacteriophages and antibiotics can significantly reduce the likelihood of resistance development. Bacteria that have acquired resistance to bacteriophages may regain susceptibility to antibiotics. For example, the combination of bacteriophages and antibiotics can reverse resistance in Pseudomonas aeruginosa.
[0153] The combination of one or more bacteriophages and one or more antibiotics of the present invention can reduce the minimum inhibitory concentration (MIC) of the antibiotic. This reduction may enable a reduction in the total antibiotic dosage and may affect the rate of antibiotic resistance development.
[0154] A combination of one or more bacteriophages and one or more antibiotics according to the present invention can enhance biofilm penetration. For example, bacteriophages may secrete enzymes capable of degrading the extracellular polymeric substrates of biofilms. This degradation can allow antibiotics to penetrate target cells more effectively. Antibiotics can enhance biofilm penetration by increasing the efficiency of phage infection through changes in cell metabolism.
[0155] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.
[0156] Figure 1 shows transmission electron microscope images of MXP1001 and MXP1002.
[0157] Figure 2 shows the results of the lysis test of Pseudomonas aeruginosa after treatment with MXP1001.
[0158] Figure 3 shows the results of the lysis test of Pseudomonas aeruginosa after treatment with MXP1002.
[0159] Figure 4 shows the adsorption test results of MXP1001.
[0160] Figure 5 shows the adsorption test results of MXP1002.
[0161] Figure 6 shows the results of a one-step proliferation test of MXP1001 in a Pseudomonas aeruginosa host.
[0162] Figure 7 shows the results of a one-step proliferation test of MXP1002 in a Pseudomonas aeruginosa host.
[0163] Figure 8 shows the results of comparing the lytic effects of MXP1001, MXP1002, and MP101 on multidrug-resistant Pseudomonas aeruginosa strain 15-4.
[0164] Figure 9 shows the results of comparing the lytic effects of MXP1001, MXP1002, and MP101 on multidrug-resistant Pseudomonas aeruginosa strain 17-6.
[0165] Figure 10 shows the results of comparing the lytic effects of MXP1001, MXP1002, and MP101 on 238 multidrug-resistant Pseudomonas aeruginosa strains.
[0166] Figure 11 shows the results of comparing the lytic effects of MP101 and other bacteriophage combinations.
[0167] Figure 12 shows the survival rate over time following amikacin treatment in mice infected with Pseudomonas aeruginosa.
[0168] Figure 13 shows the survival rate over time following treatment with a single bacteriophage or a cocktail bacteriophage in mice infected with Pseudomonas aeruginosa.
[0169] Figure 14 shows the change in antibiotic susceptibility in 7 clinical isolates of Pseudomonas aeruginosa following concomitant treatment with MP101.
[0170] Figure 15 shows the design of a checkerboard analysis plate for analyzing antibiotic synergy.
[0171] Figure 16 shows the results of measuring the minimum inhibition MOI of MP101.
[0172] Figure 17 shows the design of an antibiotic plate for analyzing antibiotic synergy.
[0173] Figure 18 shows a sinogram data template.
[0174] Figure 19 shows the results of MXP1001 and ceftazidim / avibactam combination therapy on the MXB1001 strain.
[0175] Figure 20 shows the results of MXP1001 and ceftazidim / avibactam combination therapy for 24-44 strains.
[0176] Figure 21 shows the results of MXP1001 and ceftolozane / tazobactam combination therapy on the MXB1001 strain.
[0177] Figure 22 shows the results of MXP1001 and ceftolozane / tazobactam combination therapy on 24-44 strains.
[0178] Figure 23 shows the results of the combination of MXP1001 and cefiderocol on the MXB1001 strain.
[0179] Figure 24 shows the results of MXP1001 and cefiderocol combination therapy for strains 24-44.
[0180] Figure 25 shows the results of MXP1002 and ceftazidim / avibactam combination therapy on the MXB1001 strain.
[0181] Figure 26 shows the results of MXP1002 and ceftazidim / avibactam combination therapy for strains 24-44.
[0182] Figure 27 shows the results of MXP1002 and ceftolozane / tazobactam combination therapy on the MXB1001 strain.
[0183] Figure 28 shows the results of MXP1002 and ceftolozane / tazobactam combination therapy on 24-44 strains.
[0184] Figure 29 shows the results of the combination of MXP1002 and cefiderocol on the MXB1001 strain.
[0185] Figure 30 shows the results of MXP1002 and cefiderocol combination therapy for 24-44 strains.
[0186] Figure 31 shows the results of combining MP101 and ceftazidim / avibactam on the MXB1001 strain.
[0187] Figure 32 shows the results of combining MP101 and ceftazidim / avibactam on 24-44 strains.
[0188] Figure 33 shows the results of combining MP101 and ceftolozane / tazobactam on the MXB1001 strain.
[0189] Figure 34 shows the results of combining MP101 and ceftolozane / tazobactam on 24-44 strains.
[0190] Figure 35 shows the results of combining MP101 and cefiderocol with the MXB1001 strain.
[0191] Figure 36 shows the results of combining MP101 and cefiderocol for 24-44 strains.
[0192] Figure 37 shows a graph of survival rates over time following the administration of bacteriophage, ceftazidim alone and in combination in an MXB1001 lung infection mouse model.
[0193] Figure 38 shows the increase or decrease in the number of infectious bacteria in lung tissue after administration of MP101 and meropenem alone or in combination in an MXB1001 lung infection mouse model.
[0194] Figure 39 shows the biofilm metabolic activity kinetics results following treatment with MXP1001 and ceftazidim alone in the MXB1001 strain.
[0195] Figure 40 shows the biofilm metabolic activity kinetics results following combined treatment with MXP1001 and ceftazidim in the MXB1001 strain.
[0196] Figure 41 shows the biofilm metabolic activity kinetics results following treatment with MXP1002 and ceftazidim alone in the MXB1001 strain.
[0197] Figure 42 shows the biofilm metabolic activity kinetics results following the combined treatment of MXP1002 and ceftazidim in the MXB1001 strain.
[0198] Figure 43 shows the biofilm metabolic activity kinetics results following treatment with MP101 and ceftazidim alone in the MXB1001 strain.
[0199] Figure 44 shows the results of biofilm metabolic activity kinetics following combined treatment with MP101 and ceftazidim in the MXB1001 strain.
[0200] Figure 45 shows the results of comparing the relative biofilm metabolic activity compared to the control group based on the AUC up to 24 hours.
[0201] Figure 46 shows a graph of survival rates over time following the administration of MP101 and ceftazidim alone or in combination in a 24-44 mouse model of lung infection.
[0202] Figure 47 shows a graph of survival rates over time following the administration of MP101 and meropenem alone or in combination in a 24-44 lung infection mouse model.
[0203] The present invention will be explained in detail below by way of examples. However, the following examples are merely illustrative of the present invention, and the present invention is not limited by the following examples.
[0204] Example 1. Preparation of Pseudomonas aeruginosa (host bacteria culture)
[0205] Pseudomonas aeruginosa was streaked onto a Mueller-Hinton Agar (MHA; Asan Pharmaceutical) plate and cultured in a 35°C incubator for 16 to 18 hours. One bacterial colony was taken from the plate and inoculated into 5 to 20 mL of Luria-Bertani medium (LB; BD Difco) in a test tube, and cultured for about 3 to 18 hours in a shaking incubator at 35°C at 150 to 180 rpm until the desired bacterial concentration was reached, as confirmed by measuring the optical density (OD600) at 600 nm.
[0206] The Pseudomonas aeruginosa strains used in the test included Pseudomonas aeruginosa 15-4, 17-6, and 238, as well as other strains described herein. Pseudomonas aeruginosa 15-4 showed complete resistance to aztreonam, imipenem, and meropenem, and moderate resistance to piperacillin / tazobactam. Pseudomonas aeruginosa 17-6 showed complete resistance to aztreonam, imipenem, and meropenem. Pseudomonas aeruginosa 238 showed complete resistance to imipenem and meropenem, and moderate resistance to ceftazidime and piperacillin / tazobactam.
[0207] Example 2. Preparation of bacteriophages
[0208] The bacteriophage titer (PFU / mL) was calculated by using the prepared Pseudomonas aeruginosa culture as the host, mixing the bacteriophage sample, plating it onto MHA or LB agar plates, counting the number of plaques formed after incubation, and basing the value on the number of plaques, dilution factor, and inoculation volume. The multiplicity of infection (MOI) was calculated according to the following Equation 1:
[0209] [Equation 1]
[0210] MOI = Phage Titer (PFU / mL) / Bacterial Titer (CFU / mL)
[0211] The bacteriophage was diluted with SM buffer solution (100 mM NaCl, 8 mM MgSO4·7H2O, Tris 1 mM, pH 7.5) prepared in distilled water and adjusted to an appropriate titer to achieve the desired multiplicity of infection (MOI).
[0212] Example 3. Lysis Test
[0213] A host bacterial culture prepared according to Example 1 and cultured to an OD600 of 0.2 was diluted to an OD600 of 0.02 by adding 2 mL of the culture and 18 mL of LB medium to a 50 mL centrifuge tube.
[0214] Bacteriophages prepared according to Example 2 were added to host bacterial cultures at various multiplicities of infection (MOI) ranging from about 100 to about 0.00001. The positive control for the lysis test is host bacteria not treated with bacteriophages.
[0215] The OD600 values of the treated and untreated cultures were measured at 1-hour intervals over 6 hours while incubating in a shaking incubator.
[0216] Example 4. Adsorption Test
[0217] A host bacterial culture prepared according to Example 1 was inoculated into 20 mL of LB medium and cultured until the OD600 reached 0.5.
[0218] Next, the culture was prepared according to Example 2 and exposed to a bacteriophage diluted to a multiplicity of infection (MOI) of 0.001, and then mixed by vortexing. After treatment, the culture was transferred to a 30 mL syringe, and 1 mL of each was filtered through a 0.22 μm syringe filter at 0, 1, 2, 3, 4, 5, 10, 15, 25, and 30 minutes from the time of transfer to the 30 mL syringe to obtain filtered samples.
[0219] The titer of the filtered samples was measured. Adsorption time was determined based on the correlation between time (min) and the percentage (%) of free bacteriophages (i.e., bacteriophages not adsorbed to the surface of host bacteria) relative to the initial bacteriophage titer, according to Equation 2 below:
[0220] [Equation 2]
[0221] Percentage of free bacteriophages (%) = [Titer / Initial Titer] x 100
[0222] Adsorption parameters (e.g., adsorption rate constant) were determined based on the change in the percentage (%) of free bacteriophages over time (e.g., over 25 minutes, over 40 minutes).
[0223] Example 5. One-step Growth Test
[0224] 500 μL of the host bacterial culture prepared according to Example 1 was diluted by inoculating it into 4.5 mL of LB medium contained in each of three 5 mL centrifuge tubes. Subsequently, the culture was cultured at 35°C and 180 rpm until the OD600 reached 0.2. Then, 1 mL was taken from each of the three tubes and transferred to a 1.7 mL microcentrifuge tube.
[0225] The bacteriophage prepared according to Example 2 was added to a host bacterial culture at a determined multiplicity of infection (MOI), and the mixture was reacted at room temperature for 10 minutes. The resulting sample was centrifuged at 10,000 x g for 10 minutes. The supernatant was removed, and the pellet was resuspended in 1 mL of LB medium, followed by centrifugation at 10,000 x g for 10 minutes. Subsequently, the supernatant was removed, and the sample was resuspended in 1 mL of LB medium. Afterward, 20 μL of the host bacteria-bacteriophage culture was added to 20 mL of LB medium, and the bacteriophage titer was measured at 5-minute intervals for 2 hours. Immediately after sampling, to check the bacteriophage titer, 40 μL of bacteriophage and 100 μL of host bacterial culture with an OD600 of 0.5 were added to 4 mL of melted agar.
[0226] Burst size was calculated based on the difference in bacteriophage titer between the latent period prior to lytic activity and the stabilization period after the burst.
[0227] Example 6. Characterization of MXP1001 and MXP1002
[0228] Table 1 provides an overview of the origins and phylogenetic characteristics of MXP1001, MXP1002, and MXP1003.
[0229] MXP1001MXP1002MXP1003 Origin Sewage Sewage Order Caudovirales Order Caudovirales Family Myoviridae Podoviridae Podoviridae
[0230] Table 2 shows the genomic analysis performed on MXP1001 and MXP1002.
[0231] Phage#Contigs#Bases#Genes#CDS#tRNA#rRNA#tmRNAMXP1001166,2909393000MXP1002142,5345252000
[0232] The isolated bacteriophage MXP1001 or MXP1002 was visualized using a transmission electron microscope as shown in Fig. 1.
[0233] Example 7. Activity of MXP1001 or MXP1002 against Pseudomonas aeruginosa
[0234] The lytic effects of MXP1001 and MXP1002 against Pseudomonas aeruginosa 15-4 were evaluated by performing a lytic test as described in Example 3. MXP1001 exhibited dose-dependent lytic activity against Pseudomonas aeruginosa 15-4 as evaluated by the change in OD600 over 6 hours after inoculation under conditions of multiplicity of infection (MOI) of 100, 1, 0.01, or 0.0001 (Fig. 2). MXP1002 also exhibited dose-dependent lytic activity against Pseudomonas aeruginosa 15-4 as evaluated by the change in OD600 over 6 hours after inoculation under conditions of multiplicity of infection (MOI) of 100, 1, 0.01, or 0.0001 (Fig. 3).
[0235] The adsorption of MXP1001 or MXP1002 on Pseudomonas aeruginosa 15-4 was evaluated as described in Example 4. The adsorption test results of MXP1001 (MOI 0.001) are shown in Fig. 4, and the adsorption test results of MXP1002 (MOI 0.001) are shown in Fig. 5.
[0236] The proliferation, propagation, and release of progeny phages of MXP1001 or MXP1002 within Pseudomonas aeruginosa 15-4 were confirmed through a one-step proliferation test as described in Example 5. The results of the one-step proliferation test for MXP1001 (MOI 0.001) are shown in Fig. 6, and the results of the one-step proliferation test for MXP1002 (MOI 0.001) are shown in Fig. 7.
[0237] Table 3 summarizes the parameters of MXP1001 or MXP1002 determined from the analysis of the tests described in Examples 3 to 5. These results of the characteristic analysis suggest that the likelihood of resistance development for MXP1001 is low, and that MXP1002 has high toxicity characteristics including adsorption capacity and burst size.
[0238] Parameters MXP1001MXP1002 Log (Adsorption Rate Constant) -6.07 -4.74 Burst Size 153413 Latency (Time) 1.065 1.01610 6 Number of resistant bacteria per CFU / mL: 9.42 X 10 3 7.24 X 10 4 Percentage of necrotic infections (%) 80.893.4
[0239] Example 8. Host range spot test of MXP1001 or MXP1002 against 219 strains of Pseudomonas aeruginosa
[0240] A host bacterial culture was prepared according to Example 1, and one colony was inoculated into 5 mL of LB medium in a 15 mL centrifuge tube and cultured in a shaking incubator at 35°C and 180 rpm until the OD600 value reached 0.5. 4 mL of melted agar was prepared in a 14 mL round-bottom tube, 40 μL of the host bacterial culture cultured to an OD600 of 0.5 was inoculated, and the mixture was vortexed. The bacterial sample suspended in the agar was spread evenly over the MHA medium. After the agar had completely solidified, 10 μL of bacteriophage was dropped onto the plate. The plate was left until the bacteriophage solution was completely absorbed, then inverted and cultured in a 35°C incubator for approximately 16 to 18 hours.
[0241] Next, the bacteria removal zone formed at the drop site was identified. The analysis of the bacteria removal zone was performed based on the turbidity of the corresponding area.
[0242] Table 4 shows the results of the host range spot test of MXP1001 or MXP1002 on 219 antibiotic-resistant Pseudomonas aeruginosa strains from the Republic of Korea or the United States. Each strain tested had a different antibiotic resistance profile depending on the strain and showed at least intermediate resistance (e.g., intermediate resistance or complete resistance) to one or more of amikacin, aztreonam, ceftazidime, ciprofloxacin, colistin, cefipime, gentamicin, imipenem, levofloxacin, meropenem, piperacillin, piperacillin / tazobactam, ticarcillin and / or tobramycin.
[0243] MXP1001 alone exhibited at least partial lytic activity (i.e., a clear zone without host bacterial growth or a turbid zone with some host bacterial growth) for 162 / 219 strains (74%) of the tested host bacteria. MXP1002 alone exhibited at least partial lytic activity (i.e., a clear zone without host bacterial growth or a turbid zone with some host bacterial growth) for 118 / 219 strains (54%) of the tested host bacteria. The predicted coverage of the two-phage cocktail MP101 for 219 tested strains was determined to be 182 / 219 strains (83%) by summing the number of strains in which MXP1001, MXP1002, or both MXP1001 and MXP1002 exhibited at least partial lytic activity.
[0244] Strain Source MXP1001 MXP1002 MXP1001+MXP1002 (Predicted 2-strain phage coverage) South Korea 72%(66 / 98) 55%(54 / 98) 79%(77 / 98) BEI RESOURCES 74%(23 / 31) 58%(18 / 31) 87%(27 / 31) CDC AR bank 50%(1 / 2) 0%(0 / 2) 50%(1 / 2) IPATH 81%(71 / 87) 51%(45 / 87) 87%(76 / 87) Control Strain (PAO1) 100%(1 / 1) 100%(1 / 1) 100%(1 / 1) Total 74%(162 / 219) 54%(118 / 219) 83%(182 / 219)
[0245] Example 9. Synergistic activity of MP101 compared with MXP1001 or MXP1002
[0246] A lysis test as described in Example 3 was performed to evaluate the lytic effect of MP101 (MXP1001 and MXP1002) on various Pseudomonas aeruginosa strains by comparing it with the lytic effect of MXP1001 or MXP1002 alone. Pseudomonas aeruginosa was kept as a control or treated with MP101, MXP1001, or MXP1002.
[0247] The results of the lysis tests for Pseudomonas aeruginosa 15-4, Pseudomonas aeruginosa 17-6, and Pseudomonas aeruginosa 238 are shown in Fig. 8 (MOI: 0.00001), Fig. 9 (MOI: 0.0001), and Fig. 10 (MOI: 0.0001), respectively.
[0248] Example 10. Synergistic activity of MP101 or other bacteriophage cocktails
[0249] A lysis test as described in Example 3 was performed to evaluate the lytic effect of MP101 on Pseudomonas aeruginosa 15-4 by comparing it with the lytic effect of a bacteriophage cocktail containing MXP1003 on the same strain. Pseudomonas aeruginosa was kept as a control or treated with MP101, a combination of MXP1003 and MXP1001, a combination of MXP1003 and MXP1002, or a combination of MXP1001, MXP1002, and MXP1003 under conditions of a total multiplicity of infection (MOI) of 0.00001. The results are shown in Fig. 11.
[0250] Example 11. Efficacy of bacteriophage in a systemic mouse infection model of multidrug-resistant Pseudomonas aeruginosa.
[0251] The therapeutic efficacy of bacteriophages and bacteriophage cocktails was evaluated in mice with systemic infection induced by Pseudomonas aeruginosa 15-4, a bacterial strain resistant to multiple antibiotics such as aztreonam, imipenem, meropenem, and piperacillin / tazobactam, and susceptible to amikacin.
[0252] Preparation for antibiotic and bacteriophage treatment
[0253] Amikacin disulfate salt (Sigma, A1774) was stored at 2–8°C and diluted with sterile physiological saline solution (Dai Han Isotonic Sodium Chloride Inj., Dai Han Pharm Co., Ltd) before use. Amikacin was serially diluted to doses of 6.25 mg / kg, 12.5 mg / kg, 25 mg / kg, or 50 mg / kg and used as a positive control.
[0254] Individual bacteriophages or bacteriophage cocktails were prepared according to Example 2 and stored at 2–8°C for up to 6 months. MXP1001 (potency: 1.59 χ²⁰ 10 PFU / mL; Endotoxin: 2,400 EU / mL), MXP1002 (Potency: 1.11X10 10 PFU / mL; Endotoxin: 7,640 EU / mL) and MXP1003 (potency: 1.04X10 10 PFU / mL; Endotoxin: 6,870 EU / mL) was used. In the 3-type phage cocktail, stock solutions of MXP1001, MXP1002, and MXP1003 were mixed in an activity ratio of 1:1:1, and the mixture was stored at 2–8°C. In the 2-type phage cocktail (MP101), stock solutions of MXP1001 and MXP1002 were mixed in an activity ratio of 1:1, and the mixture was stored at 2–8°C.
[0255] Test animals
[0256] Five-week-old female (20–21 g) Institute of Cancer Research (ICR) mice were purchased from HyoChang Science Inc. in South Korea. The mice were housed in polycarbonate cages measuring 200 x 260 x 130 mm (width x length x height) under conditions of a temperature of 19–23°C, relative humidity of 50–60%, air exchange rate of 10–15 times per hour, a 12-hour light-dark cycle, and a light intensity of 150–200 Lux. The mice were allowed to freely consume food and water. Teklad Certified Irradiated Global 18% Protein Rodent Diet 2918C (Envigo RMS, Inc., USA) was used as the mouse diet. Water was sterilized by heating at 121°C for 20 minutes and provided in water bottles.
[0257] Preparation of bacteria
[0258] Pseudomonas aeruginosa 15-4 stock stored at -80°C was uniformly plated onto MHA plates and incubated at 37°C for 24 hours. The bacteria were inoculated into Mueller-Hinton II (MHII) medium and incubated at 37°C in a shaking incubator at 150 rpm for 24 hours. Subsequently, the bacteria were centrifuged at 15,000 rpm for 2 minutes, the supernatant was discarded, and the pellet was resuspended in 1 mL of sterile physiological saline. OD600 was measured using a sample diluted 10-fold of the bacterial solution, and 100 μL of this sample was plated onto MHA plates and incubated overnight. The number of colonies was counted the following day, and the bacterial concentration used in the test was calculated using the ratio between the number of colonies on the plate and the OD600 value. The bacteria were inoculated into MHII medium and cultured in the same manner as before. Subsequently, the bacteria were diluted to achieve the target concentration for each animal test group. To prepare the final bacterial solution for inoculation into test animals, the bacterial solution was diluted 1:1 with 10% (w / v) porcine stomach-derived mucin (Sigma, M2378-500G) in sterile physiological saline. The final bacterial preparation containing 5% mucin in sterile physiological saline was inoculated into the abdominal cavity of test animals at a volume of 500 μL.
[0259] Treatment and Evaluation of Test Animals
[0260] Each experimental group consisted of 7 test animals. Pseudomonas aeruginosa 15-4 (1.75X10 6After administering CFU / mouse intraperitoneally, the condition of the test animals was recorded at 1-hour intervals for 3 hours. Amikacin was administered at a dose of 200 μL via the tail vein of the test animals 1 hour after inoculation with Pseudomonas aeruginosa. Bacteriophage or bacteriophage cocktail was administered undiluted at a dose of 200 μL via the tail vein of the test animals 1 hour after intraperitoneal inoculation with Pseudomonas aeruginosa. Test animals were observed every 3 hours for the first 24 hours. After the first 24 hours, the survival of the test animals was checked and recorded daily for up to 5 days. After 5 days, the condition of surviving test animals was observed, body weight was measured, and any abnormalities were checked. If no abnormalities were observed, the animals were sacrificed, and the experiment was terminated.
[0261] result
[0262] No notable adverse reactions were observed in test animals immediately after inoculation with Pseudomonas aeruginosa 15-4. 24 hours after bacterial infection, the survival and lesion formation of the mice were observed. Figures 12 and 13 and Table 5 show the 5-day survival rates of infected mice. The survival rate of negative control mice (a group infected with Pseudomonas aeruginosa but not treated with antibiotics or bacteriophages) was 0% at the 24-hour mark. Positive control mice treated with amikacin showed a dose-dependent survival rate 24 hours after infection, with survival rates of 14% at 6.25 mg / kg, 85% at 12.5 mg / kg, 100% at 25 mg / kg, and 100% at 50 mg / kg. Meanwhile, 120 hours after infection, surviving mice were found in only two high-dose amikacin groups, showing a survival rate of 71% in the 25 mg / kg amikacin group and 100% in the 50 mg / kg amikacin group (Fig. 12, Table 5).
[0263] After 24 hours of infection, 57% of mice survived in the MXP1001 treatment group, 100% in the MXP1002 treatment group, 28% in the MXP1003 treatment group, 100% in the MP101 treatment group, and 100% in the 3-type phage cocktail treatment group (Fig. 13, Table 5). After 120 hours of infection, 14% of mice survived in the MXP1001 treatment group, 28% in the MXP1002 treatment group, 14% in the MXP1003 treatment group, 85% in the MP101 treatment group, and 85% in the 3-type phage cocktail treatment group (Fig. 13, Table 5).
[0264] The mouse survival data above shows that when multidrug-resistant Pseudomonas aeruginosa infection is treated with MP101 (MXP1001 + MXP1002) or a 3-type phage cocktail (MXP1001 + MXP1002 + MXP1003), a synergistic effect is observed in vivo.
[0265] Survival rate (%) by treatment group according to time after bacterial infection Treatment time Oh 3h 9h 12h 24h 48h 7 2h 120h Control group 100 100 100 140 00 Amikacin (6.25 mg / kg) 100 100 100 141 40 00 Amikacin (12.5 mg / kg) 100 100 100 85 420 00 Amikacin (25 mg / kg) 100 100 100 100 100 71 71 71 Amikacin (50 mg / kg)100100100100100100100100100MXP100110010010010057141414MXP1002100100100100100282828MXP100310010010010028141414MP10110010010010010010085853 types Phage Cocktail100100100100100858585
[0266] Example 12. Evaluation of changes in antibiotic susceptibility following concomitant use of MP101 -1
[0267] To confirm changes in antibiotic susceptibility of pathogens when MP101 bacteriophage is used in combination with antibiotics, GN4F Sensititre, which evaluates the antibiotic susceptibility of Gram-negative bacteria, TM Antibiotic susceptibility evaluation was performed on 7 clinical isolates of Pseudomonas aeruginosa using a plate.
[0268] Seven strains of P. aeruginosa isolated from respiratory samples were cultured in MHA, and colonies were taken, suspended in 5 mL of MHB, and incubated overnight at 35°C and 180 rpm. Subsequently, 100 μL of the culture medium was inoculated into 10 mL of MHB and incubated until McFarland 0.5 was reached. MXP1001 and MXP1002 were used as bacteriophages, and phage concentrations were measured using the overlay method; the samples were stored at 4°C until use. Thermo Scientific Sensititre was used as the antibiotic panel. TM A GN4F plate was used.
[0269] To measure MIC, the strain suspension of McFarland 0.5 was diluted 1:1000 in MHB, and 50 μL was dispensed onto GN4F plates. After attaching sealing films, the plates were incubated at 35°C for 16–18 hours; subsequently, 20 μL of 0.1% TTC was added, and the plates were incubated at 35°C for an additional 2 hours to determine the MIC for each strain. In addition, to determine the minimum inhibition MOI (MIM) of phages against each host strain, single phages and mixed phages were 10 3 to 10 -6 Serially diluted within the range, cultured in a U-type 96-well plate at 35°C for 16–18 hours, and the infection rate was checked after TTC treatment.
[0270] A bacteriophage-antibiotic synergy assay (PAS (Phage-Antibiotics Synergy) assay) was performed on mixed bacteriophages. Cultured strain suspensions were diluted 1:500 in MH broth and dispensed into GN4F plates in 25 μL aliquots. Additionally, 25 μL each of MXP1001 and MXP1002, prepared according to the MOI determined based on MIM results, were dispensed. The plates were incubated at 35°C for 16–18 hours, after which TTC was added and incubated for an additional 2 hours to compare the MICs before and after bacteriophage treatment.
[0271] As a result, in all seven clinical isolates, a tendency for increased antibiotic susceptibility was confirmed in the group treated with MP101 in combination compared to the group treated with antibiotics alone. In addition, improvement in susceptibility from R to I or S, or from I to S, was observed even in strains exhibiting antibiotic resistance. A decrease in MIC was confirmed in most antibiotic classes, and changes in susceptibility were observed even under conditions of low MOI with MP101 combination (Fig. 14). These results suggest that MP101 contributes to increased susceptibility to various antibiotics and may act favorably in reducing antibiotic usage and suppressing the development of antibiotic resistance.
[0272] Example 13. Evaluation of changes in antibiotic susceptibility following concomitant use of MP101 - 2
[0273] A five-antibiotic checkerboard assay was performed to evaluate the combined effect of MP101 and antibiotics on Pseudomonas aeruginosa strain 15-4 (MXB1001) isolated from respiratory samples. After culturing the strain in MHA, colonies were taken, suspended in 5 mL of MHB, and incubated overnight at 35°C and 150 rpm. Subsequently, 100 μL of the culture medium was inoculated into 10 mL of MHB and incubated under the same conditions until reaching McFarland 0.5. Bacteriophages MXP1001 and MXP1002 were used, and phage concentrations were measured using the overlay method and stored at 4°C until use. The mixed bacteriophage MP101 was used for the combination test.
[0274] Checkerboard plates were prepared using amikacin (32 ~ 0.03125 μg / mL), ceftazidim (8 ~ 0.125 μg / mL), cefepim (8 ~ 0.125 μg / mL), meropenem (4 ~ 0.0625 μg / mL) and piperacillin / tazobactam (16 ~ 0.125 μg / mL) as test antibiotics (Fig. 15).
[0275] To determine the minimum inhibitory concentration (MIC) of antibiotics, 100 μL of cultured strain suspension was dispensed onto GN4F plates, a sealing film was attached, and the plates were incubated at 35°C for 16–18 hours. Subsequently, 20 μL of 0.1% TTC was added, and the plates were incubated at 35°C for an additional 2 hours to determine the MIC for each antibiotic.
[0276] To determine the minimum inhibitory MOI (MIM) of MP101, the CFU / mL of the host strain was measured under McFarland 0.5 conditions, and the infection rate (MOI) of the phage was calculated. Subsequently, the mixed bacteriophage MP101 was 10 3 to 10 -7Serial dilution was performed to achieve the desired range. 100 μL of the mixed phage and 100 μL of the host strain adjusted to McFarland 0.5 were dispensed into a U-type 96-well plate, sealed with a sealing film, and incubated at 35°C and 150 rpm for 16–18 hours. Subsequently, 20 μL of 0.1% TTC was added to each well, and the sample was incubated for an additional 2 hours at 35°C and 150 rpm to confirm the MIM of MP101. The results of the MIM measurement of MP101 are shown in Figure 16.
[0277] For the PAS assay, 100 μL of cultured strain 0.5 McFarland was dispensed into each antibiotic plate. MP101 was prepared according to the MOI determined from the MIM test results of the mixed bacteriophage, and 100 μL was dispensed into each antibiotic plate. The plates were sealed with film and incubated at 35°C and 150 rpm for 16–18 hours; subsequently, 20 μL of 0.1% TTC was added to each well, and the plates were incubated for an additional 2 hours at 35°C and 150 rpm. After all incubations were completed, the MIC of the bacteriophage combination for each antibiotic was determined, and the MIC results before and after phage treatment were compared. The incubation conditions were 18 hours at 35°C and 150 rpm, and the test bacterial concentration was 5.00 x 10⁶. 6 It was CFU / well, and MP101 concentrations were MOI 100, 10 -2 , 10 -4 and 10 -6 It was.
[0278] As a result, a significant change in susceptibility was observed in the group treated with MP101 bacteriophage in combination compared to the group treated with antibiotics alone. The MICs of the antibiotic-alone group were confirmed to be >8 for ceftazidime and cefepim, >4 for meropenem, >16 for piperacillin / tazobactam, and 8 for amikacin. In contrast, when MP101 was combined, the MOI was 100 and 10 -2 and 10 -4Under these conditions, the MICs of ceftazidim and cefepim decreased to ≤0.125, meropenem to ≤0.0625, piperacillin / tazobactam to ≤0.25, and amikacin to ≤0.03125, respectively. These results indicate that the combination of MP101 resulted in an increase in susceptibility of more than 256-fold for amikacin and more than 64-fold for all four other antibiotics. These changes in MIC are shown in Table 6.
[0279] In addition, MOI 10, which is a lower phage concentration -6 Increased susceptibility was maintained even in these cases. Specifically, ceftazidim, cefipim, meropenem, piperacillin / tazobactam, and amikacin showed MICs of 4, 2, 2, 16, and 8, respectively, confirming a 2-fold, 4-fold, 2-fold, 16-fold, and 8-fold increase in susceptibility compared to the antibiotic monotherapy groups. In addition, the MIM of MP101 was 10 -6 It was confirmed as.
[0280] Therefore, for the five antibiotics from various classes used in the study—amikacin, ceftazidim, cefepim, meropenem, and piperacillin / tazobactam—all phage concentrations (MOI 10 -6 A synergistic effect was confirmed at ~ 100), and especially MOI 10 -4 Under the above conditions, a very significant increase in susceptibility was observed. From this, it was confirmed that MP101 can effectively contribute to the increase in antibiotic susceptibility of the MXB1001 strain.
[0281] MIC (1000 fold) Antibiotic CAZFEPMEMPIP / TAZAMK+ MXB1001 strain > 8 > 8 > 4 > 168+ MXB1001 strain+MP101 phage MOI 10 0 ≤ 0.125≤ 0.125≤ 0.0625≤ 0.25≤ 0.03125(≥ 64x increase in susceptibility)(≥ 64x increase in susceptibility)(≥ 64x increase in susceptibility)(≥ 64x increase in susceptibility)(≥ 256x increase in susceptibility)MOI 10 -2≤ 0.125(≥ 64x increase in susceptibility)≤ 0.125(≥ 64x increase in susceptibility)≤ 0.0625(≥ 64x increase in susceptibility)≤ 0.25(≥ 64x increase in susceptibility)≤ 0.03125(≥ 256x increase in susceptibility)MOI 10 -4 ≤ 0.125(≥ 64x increase in susceptibility)≤ 0.125(≥ 64x increase in susceptibility)≤ 0.0625(≥ 64x increase in susceptibility)≤ 0.25(≥ 64x increase in susceptibility)≤ 0.03125(≥ 256x increase in susceptibility)MOI 10 -6 4 (2x increase in susceptibility) 2 (4x increase in susceptibility) 2 (2x increase in susceptibility) 1 (16x increase in susceptibility) 1 (8x increase in susceptibility) MIC: Minimum inhibitory concentration MOI: Multitiplicity of infection
[0282] Example 14. Evaluation of the combined effect of a single bacteriophage or cocktail bacteriophage and an antibiotic
[0283] A PAS kinetic assay was performed on MXB1001 strain and strains 24-44 to evaluate the combined effects of a single bacteriophage or a cocktail of bacteriophages and three antibiotics. The antibiotics used were ceftazidim / avibactam (CZA), ceftolozane / tazobactam (C / T), and cefiderocol (FDC). The types of antibiotics used in this example, test conditions, and CLSI criteria for each antibiotic are shown in Table 7.
[0284] Antibiotic MIC Range (μg / mL) CLSI (μg / mL) Susceptibility (S) Intermediate (I) Resistance (R) CZA 0.25-128≤ 8 / 4-≥ 16 / 4 C / T 0.125-64≤ 4 / 4 8 / 4≥ 16 / 4 FDC 0.03125-16≤ 48≥ 16
[0285] Pseudomonas aeruginosa strains 15-4 (MXB1001) and 24-44, isolated from respiratory samples, were used as test strains. Each strain was cultured on Mueller Hinton agar (MHA), colonies were taken, suspended in 20 mL of MHB, and adjusted to McFarland 0.5 for use. MXP1001 and MXP1002 were used as bacteriophages, and phage concentrations were measured using the overlay method and stored at 4°C until use.
[0286] Antibiotic plates were prepared to include ceftazidim / avibactam (128 / 4 ~ 0.25 / 0.0078125 μg / mL), ceftolozane / tazobactam (64 / 4 ~ 0.125 / 0.0078125 μg / mL), and cefiderocol (16 ~ 0.03125 μg / mL). The antibiotic plate design for the antibiotics synergy test is shown in Fig. 17. Additionally, the synogram data template is as shown in Fig. 18.
[0287] For the PAS kinetic assay, 0.5 McFarland (approx. 10 8100X Redox dye A was added to a bacterial suspension adjusted to CFU / mL to achieve a concentration of 1X per well, and 50 μL of this was dispensed into a prepared antibiotic plate (flat-bottom 96-well plate). Subsequently, 50 μL of bacteriophages prepared according to MOI were dispensed into each well. After attaching a sealing film to the plate, the plates were incubated in an Odin instrument at 35°C for 24 hours. After incubation, the reduction rate was calculated by measuring the OD590 nm, and additionally, the reduction rate was calculated and compared using the AUC (area under the curve) value. The incubation conditions for this example were 24 hours at 35°C, and the bacterial concentration was 5.00E+06 CFU / well. The bacteriophage concentration used was MOI 10 2 , 10 1 , 10 0 , 10 -2 , 10 -4 , 10 -6 and 10 -7 It was a condition.
[0288] The results for the MXP1001 single bacteriophage are as shown in Figures 19 to 24. Specifically, the results of the combination of MXP1001 and ceftazidim / avibactam (CZA) for the MXB1001 strain are shown in Fig. 19, the results of the combination of MXP1001 and ceftazidim / avibactam (CZA) for strains 24-44 are shown in Fig. 20, the results of the combination of MXP1001 and ceftolozane / tazobactam (C / T) for the MXB1001 strain are shown in Fig. 21, the results of the combination of MXP1001 and ceftolozane / tazobactam (C / T) for strains 24-44 are shown in Fig. 22, the results of the combination of MXP1001 and cefiderocol (FDC) for the MXB1001 strain are shown in Fig. 23, and the results of the combination of MXP1001 and cefiderocol (FDC) for strains 24-44 are shown in Fig. 24. In the case of MXP1001 single bacteriophage, for both MXB1001 strain and 24-44 strains, the inhibitory effect was significantly greater in the group treated with both bacteriophage and antibiotic compared to the group treated with antibiotic alone (no phage) for all antibiotics, and thus a synergistic effect with each antibiotic was confirmed.
[0289] As shown in Figures 19, 21, and 23, for the MXB1001 strain, bacterial growth tended to be more effectively inhibited in the group treated with MXP1001 in combination with ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol, respectively, compared to the group treated with antibiotics alone without bacteriophage treatment. In particular, the inhibitory effect was confirmed at both 8-hour and 24-hour measurement points, confirming a synergistic effect between MXP1001 and each antibiotic.
[0290] In addition, as shown in Figures 20, 22, and 24, superior proliferation inhibitory effects were confirmed in the MXP1001 combination treatment group compared to the antibiotic monotherapy group for ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol, respectively, in strains 24-44. This demonstrates that MXP1001 exhibits a synergistic effect when combined with all tested antibiotics, even for strains 24-44.
[0291] As described above, MXP1001 monobacteriophage showed improved antibacterial effects compared to antibiotic-alone treatment groups when combined with ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol in both MXB1001 strain and strains 24-44, and it was confirmed that it showed synergistic effects with all three antibiotics tested.
[0292] The results for MXP1002 single bacteriophage are as shown in FIGS. 25 to 30. Specifically, the results of the combination of MXP1002 and ceftazidim / avibactam (CZA) for the MXB1001 strain are shown in Fig. 25, the results of the combination of MXP1002 and ceftazidim / avibactam (CZA) for strains 24-44 are shown in Fig. 26, the results of the combination of MXP1002 and ceftolozane / tazobactam (C / T) for the MXB1001 strain are shown in Fig. 27, the results of the combination of MXP1002 and ceftolozane / tazobactam (C / T) for strains 24-44 are shown in Fig. 28, the results of the combination of MXP1002 and cefiderocol (FDC) for the MXB1001 strain are shown in Fig. 29, and the results of the combination of MXP1002 and cefiderocol (FDC) for strains 24-44 are shown in Fig. 30.
[0293] As shown in Figures 25 and 27, in the MXB1001 strain, the MXP1002 combination treatment group showed a superior bacterial growth inhibitory effect against ceftazidim / avibactam and ceftolozane / tazobactam compared to the antibiotic-alone treatment group without bacteriophage treatment.
[0294] As shown in Figures 26, 28, and 30, for strains 24-44, superior bacterial growth inhibitory effects were confirmed in the MXP1002 combination treatment group compared to the antibiotic-alone treatment group for ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol, respectively. Therefore, it was confirmed that the MXP1002 monobacteriophage exhibits a synergistic effect when combined with all three antibiotics tested for strains 24-44.
[0295] As described above, it was confirmed that the MXP1002 single bacteriophage showed synergistic effects when combined with ceftazidim / avibactam and ceftolozane / tazobactam in the MXB1001 strain, and synergistic effects when combined with ceftazidim / avibactam, ceftolozane / tazobactam and cefiderocol in the 24-44 strain.
[0296] The results for the MP101 cocktail bacteriophage are shown in Figures 31 to 36. Specifically, the results of the combination of MP101 and ceftazidim / avibactam (CZA) for the MXB1001 strain are shown in Figure 31; the results of the combination of MP101 and ceftazidim / avibactam (CZA) for strains 24-44 are shown in Figure 32; the results of the combination of MP101 and ceftolozane / tazobactam (C / T) for the MXB1001 strain are shown in Figure 33; the results of the combination of MP101 and ceftolozane / tazobactam (C / T) for strains 24-44 are shown in Figure 34; the results of the combination of MP101 and cefiderocol (FDC) for the MXB1001 strain are shown in Figure 35; and the results of the combination of MP101 and cefiderocol (FDC) for strains 24-44 are shown in Figure 36.
[0297] As shown in Figures 31, 33, and 35, in the MXB1001 strain, the inhibitory effect on bacterial growth was greater in the MP101 combination treatment group compared to the antibiotic-alone treatment group without bacteriophage treatment for ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol, respectively. In addition, as shown in Figures 32, 34, and 36, for strains 24-44, the MP101 combination treatment group showed a superior inhibitory effect on bacterial growth compared to the antibiotic-alone treatment group for all antibiotics tested.
[0298] In particular, the MP101 cocktail bacteriophage showed the best overall synergy when combined with all antibiotics tested in both the MXB1001 strain and strains 24-44. This means that the combination effect with antibiotics can be further enhanced when using the cocktail bacteriophage MP101 compared to when using the single bacteriophages MXP1001 or MXP1002.
[0299] As described above, the MP101 cocktail bacteriophage showed the best antibacterial effect when combined with ceftazidim / avibactam, ceftolozane / tazobactam, and cefiderocol in both the MXB1001 strain and strains 24-44, and was confirmed to provide the strongest synergistic effect for all three antibiotics tested.
[0300] Example 15. Evaluation of the effect of co-administration of MP101 and antibiotics in a mouse model
[0301] In a mouse lung infection model using Pseudomonas aeruginosa strain 15-4 (MXB1001), the effect of co-administration of MP101 and antibiotics on improving survival rate and reducing infectious bacteria in lung tissue was evaluated.
[0302] Survival rate evaluation
[0303] After acclimatizing 6-week-old male ICR mice for 1 week, Pseudomonas aeruginosa 15-4 was inoculated 2×10 8The drug was prepared at a concentration of 20 μL CFU / 20 μL, and 10 μL was administered intranasally into each nostril while the mice were immobilized to induce infection. Two hours after infection, a negative control group, an MP101 monotherapy group, a ceftazidim monotherapy group, and a combination of MP101 and ceftazidim groups were established, and the drug was administered as a single dose. MP101 was 1×10 10 The subjects were administered at a dose of PFU / head, and ceftazidime was administered at doses of 100 mg / kg, 50 mg / kg, and 25 mg / kg, respectively. The drugs were slowly infused in 0.2 mL a day via the tail vein. During the infection date and observation period, the types, onset dates, and severity of general symptoms, including death, were observed up to 96 hours after infection and recorded for each individual. Information on the test group is shown in Table 8, and the number of surviving subjects and survival rates by time are shown in Table 9. Additionally, graphs of survival rates by time according to the administration of bacteriophage, antimicrobial agents alone, and in combination are shown in Figure 37.
[0304] Group Number of Animals (heads) Administered Substance Dosage Phage (pfu / head) Antibiotic 18 Control Negative Control Group Vehicle (Vehicle: 50 mM Tris + 20 mM MgSO4 + 0.9% NaCl) 28 MP 10 1 Test Substance 1 X 10 10 (4 x 10 11 PFU / kg)-38 Ceftazidim_High Concentration Test Substance-100 mg / kg 48 Ceftazidim_Medium Concentration Test Substance-50 mg / kg 58 Ceftazidim_Low Concentration Test Substance-25 mg / kg 68MP101 + Ceftazidim_High Concentration Test Substance 1 X 10 10 (4 x 10 11 PFU / kg)100 mg / kg78MP101 + Ceftazidim_Medium Concentration Test Substance 1 X 10 10 (4 x 10 11 PFU / kg)50 mg / kg 88MP101 + Ceftazidime_Low Concentration Test Substance 1 X 10 10 (4 x 10 11 PFU / kg) 25 mg / kg
[0305] Group 0 h(D 0)24 h(D+1)48 h(D+2)72 h(D+3)96 h(D+4)G1Control8(100)0(0)0(0)0(0)0(0)G2MP1018(100)5(62.5)3(37.5)3(37.5)3(37.5)G3Ceftazidim_High Concentration8(100)4(50)3(37.5)3(37.5)3(37.5)G4Ceftazidim_Medium Concentration8(100)3(37.5)2(25)2(25)2(25)G5Ceftazidim_Low Concentration8(100)1(12.5)1(12.5)1(12.5)1(12.5)G6MP101 + Ceftazidim_High Concentration 8(100)8(100)8(100)8(100)8(100)G7MP101 + Ceftazidim_Medium Concentration 8(100)7(87.5)7(87.5)6(75)6(75)G8MP101 + Ceftazidim_Low Concentration 8(100)8(100)8(100)5(62.5)5(62.5)
[0306] As a result, the phage-antibiotic combination therapy groups at all concentrations showed superior survival improvement compared to the antibiotic monotherapy groups. Specifically, the final survival rates of the ceftazidim monotherapy groups were confirmed to be 37.5% at 100 mg / kg, 25% at 50 mg / kg, and 12.5% at 25 mg / kg. In contrast, survival rates of 100%, 75%, and 62.5% were confirmed in the MP101 and ceftazidim combination therapy groups, respectively. Notably, the survival rate of the group administered MP101 in combination with the lowest concentration of ceftazidim (25 mg / kg) was 62.5%, which was higher than the 37.5% survival rate of the high concentration (100 mg / kg) ceftazidim monotherapy group. This suggests that the combination therapy of MP101 and ceftazidim can improve therapeutic efficacy while reducing antibiotic usage.
[0307] Evaluation of reduction in infectious agents within lung tissue
[0308] Pseudomonas aeruginosa15-4 was administered to 6-week-old male ICR mice at a rate of 1.5 x 10 8Infection was induced by preparing the solution at a concentration of 20 μL CFU and administering 10 μL intranasally into each nostril. Two hours after infection, a negative control group, a meropenem monotherapy group, an MP101 monotherapy group, and a combination of MP101 and meropenem were established, and the drug was administered as a single dose. MP101 was 1×10 7 The drugs were administered at a dose of PFU / head, and meropenem was administered at a dose of 50 mg / kg or 25 mg / kg. In the case of concomitant administration, MP101 was administered first, followed by meropenem one hour later. Subsequently, when the first death occurred in the control group, all mice in the groups were euthanized, and the lungs were excised, homogenized, and cultured on a medium to measure the number of residual bacteria (CFU) in the lung tissue. Information on the test groups is shown in Table 10, and the efficacy in reducing infectious bacteria is shown in Figure 38.
[0309] Group Number of Animals (Heads) Administered Substance Phage Dose (PFU / head) Control 5 Control Negative Control Group Vehicle (Vehicle: 50 mM Tris + 20 mM MgSO4 + 0.9% NaCl) A5 Meropenem (50 mg / kg) Positive Control Group B5 Meropenem (25 mg / kg) Positive Control Group C5 MP101 (MXP1001 + MXP1002) Test Substance 1 X 10 7 (4 x 10 8 PFU / kg)D5 Meropenem (50 mg / kg) + MP101 Test Substance 1 X 10 7 (4 x 10 8 PFU / kg) E5 Meropenem (25 mg / kg) + MP101 Test Substance 1 X 10 7 (4 x 10 8 PFU / kg)
[0310] As a result, when the concentration of infectious bacteria in lung tissue was measured at 20 hours after infection, a superior bacterial reduction effect was confirmed in the group administered meropenem and MP101 in combination compared to the groups administered meropenem alone or MP101 alone. Specifically, a decrease of 0.05 to 0.88 Log10 relative to the number of inoculated infectious bacteria was observed in the antibiotic-alone group, whereas a decrease of 1.99 to 2.18 Log10 was confirmed in the phage-antibiotic combination group. Therefore, it was confirmed that the combined administration of MP101 and meropenem exhibited a distinct synergistic effect in reducing infectious bacteria in lung tissue.
[0311] Example 16. Evaluation of Biofilm Inhibitory Effect
[0312] Biofilm removal kinetics analysis was performed to evaluate the biofilm inhibitory effects of MXP1001, MXP1002, and MP101 and ceftazidime, either alone or in combination, on the MXB1001 strain. Metabolic activity within the biofilm for 48 hours after treatment with bacteriophages and ceftazidime, either alone or in combination, was measured by the color development (OD590) following the reduction of Redox dye, and the relative biofilm metabolic activity of each treatment group was compared by calculating the AUC up to 24 hours.
[0313] Specifically, for strain culture, one colony was taken and pre-cultured in LB broth, then 100 μL of the pre-culture solution was inoculated into 10 mL of LB broth and cultured at 35°C and 180 rpm for 16 to 18 hours. Afterward, the culture solution was diluted with LB to adjust the OD600 to 0.2.
[0314] To induce biofilm formation, 150 μL of a strain suspension adjusted to an OD600 of 0.2 was dispensed into 96-well plates and incubated at 37°C for 24 hours. After incubation, the supernatant was removed from each well, and each well was washed three times with 200 μL of 1× PBS. Subsequently, the wash solution was completely removed by dabbing with a paper towel.
[0315] To measure biofilm metabolic activity, 180 μL of LB broth was dispensed into each of the 8 wells for the positive control. For the bacteriophage-alone treatment groups, MXP1001, MXP1002, and MP101 (MXP1001+MXP1002) were administered at a dose of 1 1 / 10⁻¹⁰ 6 PFU / mL to 1X10 9 The antibiotic was diluted in LB broth to a concentration of PFU / mL and dispensed at a rate of 180 μL per condition into 8 wells. For the antibiotic-alone treatment group, ceftazidime was diluted in LB broth to concentrations of 4 μg / mL and 40 μg / mL, and 180 μL of each concentration was dispensed into 8 wells. For the bacteriophage and antibiotic combined treatment group, 90 μL of bacteriophage prepared at a 2x concentration and 90 μL of antibiotic were added to the same wells. After sample dispensing, 20 μL of Redox dye A at a 10x concentration diluted in LB was dispensed into each well. After attaching a sealing film, OD590 was measured at 20-minute intervals for 48 hours at 35°C using an Odin instrument.
[0316] The results of the analysis of biofilm removal and metabolic activity kinetics in the MXB1001 strain are shown in Figures 39 to 44. Specifically, the results of treatment with MXP1001 and ceftazidim alone are shown in Figure 39, the results of treatment with MXP1001 and ceftazidim in combination are shown in Figure 40, the results of treatment with MXP1002 and ceftazidim alone are shown in Figure 41, the results of treatment with MXP1002 and ceftazidim in combination are shown in Figure 42, the results of treatment with MP101 and ceftazidim alone are shown in Figure 43, and the results of treatment with MP101 and ceftazidim in combination are shown in Figure 44. In addition, the results of comparing the relative biofilm metabolic activity values compared to the control group based on the AUC up to 24 hours are shown in Table 11, and the results plotted as a graph are shown in Figure 45.
[0317] As a result, the effect of reducing biofilm metabolic activity was confirmed in the MXP1001 and MXP1002 single-treatment groups, and the inhibitory effect on biofilm metabolism was even greater when treated with the MP101 cocktail. In addition, while biofilm metabolic activity was partially inhibited in the bacteriophage and ceftazidim single-treatment groups, biofilm metabolic activity was significantly reduced in the bacteriophage and ceftazidim combined treatment group.
[0318] Specifically, as a result of comparing relative biofilm metabolic activity against the control group based on AUC up to 24 hours, MXP1001 was 1×10 6 PFU / mL and 1X10 9 At PFU / mL, values were 17% and 18%, respectively, and in the group treated with MXP1001 and ceftazidim, the levels decreased to 4 to 8%. MXP1002 showed 51% and 56%, respectively, at the same concentration, and in the group treated with ceftazidim, the levels decreased to 3 to 4%. MP101 showed 9% and 3% in the monotherapy group and 4 to 5% in the group treated with ceftazidim. On the other hand, the group treated with ceftazidim monotherapy showed levels of 48 to 58% at 4 μg / mL and 42 to 53% at 40 μg / mL. Therefore, the groups treated with a single bacteriophage or MP101 and ceftazidim showed significantly lower AUC values compared to the control group across all concentration groups, and a particularly superior biofilm inhibition effect was confirmed in the combination treatment group.
[0319] As described above, MXP1001, MXP1002, and MP101 have the effect of reducing biofilm metabolic activity in the MXB1001 strain, and it was confirmed that this effect is further enhanced when combined with ceftazidim. In particular, the MP101 cocktail bacteriophage exhibited excellent biofilm inhibitory effects even when treated alone, and it was confirmed to provide a more significant synergistic effect when combined with ceftazidim. Therefore, MP101 can be usefully utilized for the control and inhibition of infections associated with biofilm formation or maintenance when combined with antibiotics.
[0320] Phage1E+06 PFU / mL1E+09 PFU / mL1E+06 PFU / mL+4 ug / mL CAZ1E+06 PFU / mL+40 ug / mL CAZ1E+09 PFU / mL+4 ug / mL CAZ1E+09 PFU / mL+40 ug / mL CAZ4 ug / mL CAZ40 ug / mL CAZMXP100117%18%7%8%4%5%48%42%MXP100251%56%3%4%3%4%55%47%MP1019%3%4%4%4%5%58%53%
[0321] Example 17. Evaluation of the effect of co-administration of MP101 and antibiotics in vivo
[0322] Evaluation of survival rates following combination therapy of MP101 and ceftazidim
[0323] After acclimatizing ICR male mice for 1 week, Pseudomonas aeruginosa 24-44 was introduced at a rate of 1 10⁻¹⁰ 8 Prepared at a concentration of 20 μL CFU, mice were immobilized using dorsal trabecular skin fixation and maintained in a supine position; infection was induced by intranasal administration of 20 μL into one nostril. Two hours after infection, the provocation control group and the monotherapy group MP101 1X10 8 (5X10 7 +5X10 7 ) PFU / head, MP101 1X10 10 (5X10 9 +5X10 9Groups were established for PFU / head, ceftazidim 50 mg / kg or 100 mg / kg monotherapy, and MP101 and ceftazidim combination therapy, and the drug was administered as a single dose. The animals were placed in a restraint frame and the drug was slowly infused through a caudal vein over 1 minute. The types, onset dates, and severity of general symptoms, including death, were observed and recorded individually up to 168 hours after infection during the infection and observation period.
[0324] Information on the test group for the ceftazidim combination administration group is shown in Table 12, and the number of surviving individuals and survival rates over time are shown in Table 13. In addition, graphs of survival rates over time according to the administration of bacteriophage, antimicrobial agent alone, and in combination are shown in Figure 46.
[0325] Group Number of Animals (heads) Administered Substance Dosage Phage (pfu / head) Antibiotic 18 Control Negative Control Group Vehicle (Vehicle: 50 mM Tris + 20 mM MgSO4 + 0.9% NaCl) 28 MP101_Low Concentration Test Substance 1 X 10 8 -38MP101_High Concentration Test Substance 1 X 10 10 -48 Ceftazidim_50 mg / kg Test Substance-50 mg / kg 58 Ceftazidim_100 mg / kg Test Substance-100 mg / kg 68 MP101 Low + Ceftazidim Low Test Substance 1 X 10 8 50 mg / kg 78MP101 Low + Ceftazidim High Test Substance 1 X 10 8 100 mg / kg 88MP101 High + Ceftazidime Low Test Substance 1 X 10 10 50 mg / kg 98MP101 High + Ceftazidim High Test Substance 1 X 10 10 100 mg / kg
[0326] Group 0 h(D 0)24 h(D+1)48 h(D+2)72 h(D+3)96 h(D+4)120 h(D+5)144 h(D+6)168 h(D+7)G1Control8(100)0(0)0(0)0(0)0(0)0(0)0(0)0(0)G2MP101_Low Concentration8(100)4(50)3(37.5)3(37.5)3(37.5)3(37.5)3(37.5)3(37.5)G3MP101_High Concentration8(100)5(62.5)4(50)4(50)4(50)4(50)4(50)4(50)G4Ceftazidim_50 mg / kg 8(100)4(50)2(25)2(25)2(25)2(25)2(25)2(25)G5 Ceftazidim_100 mg / kg 8(100)4(50)2(25)2(25)2(25)2(25)2(25)2(25)2(25)G6 MP101 Low + Ceftazidim Low 8(100)4(50)2(25)2(25)2(25)2(25)2(25)2(25)2(25)G7 MP101 Low + Ceftazidim High 8(100)5(62.5)1(12.5)1(12.5)1(12.5)1(12.5)1(12.5)1(12.5)G8 MP101 High + Ceftazidim Low 8(100)6(75)6(75)6(75)6(75)6(75)6(75)6(75)G9MP101 High + Septazidim High 8(100)6(75)6(75)5(62.5)5(62.5)5(62.5)5(62.5)5(62.5)5(62.5)
[0327] As a result, a significantly superior improvement in survival rates was confirmed in the high-dose MP101 administration group and the ceftazidim combination therapy group compared to the antibiotic monotherapy group. Specifically, while the final survival rate for the ceftazidim 50 mg / kg or 100 mg / kg monotherapy groups was 25%, the high-dose MP101 (1X10 10The final survival rate for the group administered with a combination of MP101 (PFU / head) and ceftazidim 50 mg / kg was 75%, while the final survival rate for the group administered with a high concentration of MP101 and ceftazidim 100 mg / kg was 62.5%. In contrast, the group administered with a low concentration of MP101 and ceftazidim showed limited significant improvement compared to the antibiotic monotherapy group. In particular, when a high concentration of MP101 was administered with a low dose of ceftazidim (50 mg / kg), a superior survival rate was confirmed compared to the group administered with a high dose of ceftazidim monotherapy. This suggests that the combination of MP101 and ceftazidim can improve survival rates while reducing antibiotic usage.
[0328] Survival rate evaluation following combination therapy of MP101 and meropenem
[0329] After acclimatizing ICR male mice for one week, Pseudomonas aeruginosa was introduced into 1x10 oz, in which a 100% lethality rate within 24 hours was observed in a preliminary study. 8 Nasal infection was administered at a concentration of CFU / head. Specifically, Pseudomonas aeruginosa 24-44 was 1×10⁻¹⁰ 8 The solution was prepared at a concentration of 20 μL CFU / 20 μL, and 20 μL was administered intranasally into one nostril while mice were immobilized via dorsal cervical skin fixation and maintained in a supine position. Two hours after infection, a single dose of the drug was administered to a provocation control group, an MP101 monotherapy group, a meropenem monotherapy group, and a combination therapy group of MP101 and meropenem. MP101 was 1×10 8 (5X10 7 +5X10 7 ) PFU / head or 1X10 10 (5X10 9 +5X10 9) was administered at a dose of PFU / head, and meropenem was administered at doses of 3 mg / kg, 10 mg / kg, or 50 mg / kg. The drugs were slowly infused over 1 minute via a caudal vein after the animals were placed in a restraint frame. The type, onset date, and severity of general symptoms, including death, were observed and recorded individually up to 168 hours after infection during the infection and observation period.
[0330] Information on the test group for the meropenem combination therapy group is shown in Table 14, and the number of surviving individuals and survival rates over time are shown in Table 15. In addition, graphs of survival rates over time according to the administration of bacteriophage, antimicrobial agent alone, and in combination are shown in Figure 47.
[0331] Group Number of Animals (heads) Administered Substance Dosage Phage (pfu / head) Antibiotic 18 Control Negative Control Group Vehicle (Vehicle: 50 mM Tris + 20 mM MgSO4 + 0.9% NaCl) 28 MP101_Low Concentration Test Substance 1 X 10 8 -38MP101_High Concentration Test Substance 1 X 10 10 -48 Meropenem_3 mg / kg Test Substance-3 mg / kg 58 Meropenem _10 mg / kg Test Substance-10 mg / kg 68 Meropenem_50 mg / kg Test Substance-50 mg / kg 78 MP101 Low + Meropenem Low Test Substance 1 X 10 8 3 mg / kg 88MP101 Low + Meropenem Medium Test Substance 1 X 10 8 10 mg / kg 98MP101 High + Meropenem Low Test Substance 1 X 10 10 3 mg / kg 108MP 101 High + Meropenem Medium Test Substance 1 X 10 10 10 mg / kg
[0332] Group 0 h(D 0)24 h(D+1)48 h(D+2)72 h(D+3)96 h(D+4)120 h(D+5)144 h(D+6)168 h(D+7)G1Control8(100)0(0)0(0)0(0)0(0)0(0)0(0)0(0)G2MP101_Low Concentration8(100)3(37.5)1(12.5)1(12.5)1(12.5)1(12.5)1(12.5)1(12.5)G3MP101_High Concentration8(100)5(62.5)3(37.5)3(37.5)3(37.5)3(37.5)3(37.5)3(37.5)G4Meropenem_3 mg / kg 8(100)2(25)2(25)2(25)2(25)2(25)2(25)2(25)G5 Meropenem _10 mg / kg 8(100)6(75)3(37.5)2(25)2(25)2(25)2(25)2(25)G6 Meropenem_50 mg / kg 8(100)8(100)6(75)4(50)3(37.5)3(37.5)3(37.5)3(37.5)G7 MP101 Low + Meropenem Low 8(100)4(50)2(25)2(25)1(12.5)1(12.5)1(12.5)G8 MP101 Low + Meropenem Middle 8(100)8(100)6(75)5(62.5)5(62.5)5(62.5)5(62.5)5(62.5)G9MP101 High + Meropenem Low 8(100)8(100)6(75)5(62.5)2(25)2(25)2(25)2(25)G10MP101 High + Meropenem Middle 8(100)8(100)8(100)7(87.5)4(50)4(50)4(50)4(50)
[0333] As a result, a significantly superior improvement in survival rate was confirmed in the group administered MP101 in combination with meropenem compared to the group administered meropenem alone. Specifically, the final survival rate of the meropenem 10 mg / kg monotherapy group was 25%, but the low concentration of MP101 (1×10 8 The final survival rate of the group administered with the combination of PFU / head) and meropenem 10 mg / kg was 62.5%, and MP101 high concentration (1X10 10The final survival rate of the group administered with a combination of MP101 (PFU / head) and meropenem 10 mg / kg was 50%. In contrast, the group administered with meropenem 3 mg / kg showed limited significant improvement compared to the monotherapy group. In particular, when low concentration MP101 was administered in combination with meropenem 10 mg / kg, a superior survival rate was confirmed compared to the group administered with high dose meropenem (50 mg / kg) alone. This suggests that the combination of MP101 and meropenem can improve survival rates while reducing antibiotic usage.
[0334] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.
[0335] The scope of the present invention is defined by the claims set forth below, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts thereof should be interpreted as being included within the scope of the present invention.
[0336]
[0337] [Consignment Number]
[0338] Depository Name: Korean Culture Collection Center (KCCM)
[0339] Trustee Number: KCCM13247P
[0340] Date of Trust: 20221013
[0341]
[0342] Depository Name: Korean Culture Collection Center (KCCM)
[0343] Trustee Number: KCCM13335P
[0344] Date of Trust: 20230224
[0345]
[0346]
[0347]
[0348]
[0349]
Claims
1. Bacteriophage MXP1001, deposited under accession number KCCM13247P, capable of lysing Pseudomonas aeruginosa.
2. In claim 1, the bacteriophage MXP1001 comprises a genome comprising a nucleotide sequence having 90% or more sequence identity with respect to the nucleotide sequence of SEQ ID NO.
1.
3. In paragraph 1, the above-mentioned Pseudomonas aeruginosa is bacteriophage MXP1001, which is an antibiotic-resistant Pseudomonas aeruginosa.
4. In claim 1, the bacteriophage MXP1001 is a bacteriophage that enhances the susceptibility of Pseudomonas aeruginosa to antibiotics.
5. Bacteriophage MXP1002, deposited under accession number KCCM13335P, capable of lysing Pseudomonas aeruginosa.
6. In paragraph 5, bacteriophage MXP1002 comprises a genome comprising a nucleotide sequence having 90% or more sequence identity with respect to the nucleotide sequence of SEQ ID NO.
2.
7. In paragraph 5, the above-mentioned Pseudomonas aeruginosa is bacteriophage MXP1002, which is an antibiotic-resistant Pseudomonas aeruginosa.
8. In paragraph 5, the bacteriophage MXP1002 is a bacteriophage that enhances the susceptibility of Pseudomonas aeruginosa to antibiotics.
9. An antimicrobial composition comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
10. An antibacterial composition according to claim 9, wherein the antibacterial agent is against Pseudomonas aeruginosa.
11. An antimicrobial composition according to claim 9, wherein the composition further comprises an antibiotic.
12. An antimicrobial composition according to claim 11, wherein the antibiotic comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof.
13. In Paragraph 12, (a) The above carbapenem antibiotics include doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or combinations thereof; (b) The above aminoglycoside antibiotics include amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; (c) The above cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotechitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The above penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The above nitrofuran antibiotic contains nitrofurantoin; (h) The above sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) An antimicrobial composition comprising the above-mentioned polymyxin antibiotic colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof.
14. A composition for inhibiting biofilm formation comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
15. A composition for inhibiting biofilm formation according to claim 14, wherein the biofilm is produced by Pseudomonas aeruginosa.
16. A composition for inhibiting biofilm formation according to claim 14, wherein the composition further comprises an antibiotic.
17. A composition for inhibiting biofilm formation according to claim 16, wherein the antibiotic comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof.
18. In Paragraph 17, (a) The above carbapenem antibiotics include doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or combinations thereof; (b) The above aminoglycoside antibiotics include amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; (c) The above cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotechitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The above penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The above nitrofuran antibiotic contains nitrofurantoin; (h) The above sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) A composition for inhibiting biofilm formation, wherein the polymyxin antibiotic comprises colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof.
19. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
20. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein, in claim 19, the bacteriophage MXP1001 or bacteriophage MXP1002 is lysed to Pseudomonas aeruginosa.
21. A pharmaceutical composition for the prevention or treatment of a Pseudomonas aeruginosa infection or a disease caused by a Pseudomonas aeruginosa infection, wherein the disease caused by the Pseudomonas aeruginosa infection is one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema.
22. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the above-mentioned Pseudomonas aeruginosa is an antibiotic-resistant Pseudomonas aeruginosa.
23. In paragraph 19, the total dose of bacteriophages included in the composition is 1 x 10 2 PFU / mL to 1X10 15 A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection, with a PFU / mL phosphorus content.
24. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the composition further comprises an antibiotic in accordance with claim 19.
25. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the antibiotic according to claim 24 comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof.
26. In Paragraph 25, (a) The above carbapenem antibiotics include doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or combinations thereof; (b) The above aminoglycoside antibiotics include amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; (c) The above cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotechitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The above penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The above nitrofuran antibiotic contains nitrofurantoin; (h) The above sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the polymyxin antibiotic comprises colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof.
27. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the composition may be administered orally or parenterally.
28. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the parenteral administration according to claim 27 is subcutaneous, intradermal, intravenous, arterial, muscular, abdominal cavity, dura mater, joint, synovial sac, sternum, lesion, or rectal administration.
29. A pharmaceutical composition for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the composition is formulated for oral, subcutaneous, intradermal, intravenous, arterial, muscular, abdominal, dura mater, joint, synovial sac, sternum, lesion, or rectal administration.
30. A kit for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof; and instructions.
31. A kit for the prevention or treatment of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein the kit further comprises an antibiotic.
32. A food composition for the prevention or improvement of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, comprising bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
33. A food composition for the prevention or improvement of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection, wherein, in paragraph 32, the bacteriophage MXP1001 or bacteriophage MXP1002 enhances the susceptibility of Pseudomonas aeruginosa to antibiotics.
34. A food composition for the prevention or improvement of a Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, wherein the disease caused by the Pseudomonas aeruginosa infection is one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema.
35. In paragraph 32, the total dose of bacteriophages included in the composition is 1 x 10 2 PFU / mL to 1X10 15 PFU / mL phosphorus, food composition for the prevention or improvement of Pseudomonas aeruginosa infection or diseases caused by Pseudomonas aeruginosa infection.
36. A method for preventing, treating, or improving a Pseudomonas aeruginosa infection or a disease caused by a Pseudomonas aeruginosa infection, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual.
37. A method for preventing, treating, or improving Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, wherein the bacteriophage MXP1001 comprises a genome having a nucleotide sequence having 90% or more sequence identity with respect to the nucleotide sequence of SEQ ID NO.
1.
38. A method for preventing, treating, or improving Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, wherein the bacteriophage MXP1002 comprises a genome having a nucleotide sequence having 90% or more sequence identity with respect to the nucleotide sequence of SEQ ID NO.
2.
39. A method for the prevention, treatment, or improvement of a Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, wherein the disease caused by the above Pseudomonas aeruginosa infection is one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema.
40. A method for the prevention, treatment, or improvement of a Pseudomonas aeruginosa infection or a disease caused by a Pseudomonas aeruginosa infection, wherein the method further comprises the step of administering in combination with an antibiotic in accordance with paragraph 36.
41. A method for preventing, treating, or improving a Pseudomonas aeruginosa infection or a disease caused by Pseudomonas aeruginosa infection, wherein the antibiotic comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof, according to claim 40.
42. In Paragraph 41, (a) The above carbapenem antibiotics include doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or combinations thereof; (b) The above aminoglycoside antibiotics include amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; (c) The above cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotechitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The above penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The above nitrofuran antibiotic contains nitrofurantoin; (h) The above sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) A method for preventing, treating, or improving a disease caused by Pseudomonas aeruginosa infection, wherein the above-mentioned polymyxin antibiotic comprises colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof.
43. A method for the prevention, treatment, or improvement of a Pseudomonas aeruginosa infection or a disease caused by a Pseudomonas aeruginosa infection, wherein the antibiotic is administered simultaneously, sequentially, or separately with bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof.
44. In paragraph 36, the total dose of bacteriophage administered to the individual is 1 x 10 2 PFU / mL to 1X10 15 PFU / mL phosphorus, method for prevention, treatment, or improvement of Pseudomonas aeruginosa infection or disease caused by Pseudomonas aeruginosa infection.
45. A method for enhancing antibiotic susceptibility of Pseudomonas aeruginosa, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to an individual that has a Pseudomonas aeruginosa infection or is at risk of Pseudomonas aeruginosa infection.
46. A method for enhancing antibiotic susceptibility of Pseudomonas aeruginosa, comprising the step of administering in combination with an antibiotic in accordance with paragraph 45.
47. A method for enhancing antibiotic susceptibility of Pseudomonas aeruginosa according to claim 46, wherein the antibiotic comprises amikacin, ceftazidim, cefepim, meropenem, piperacillin / tazobactam, ceftazidim / avibactam, ceftolozane / tazobactam, cefiderocol, or a combination thereof.
48. In paragraph 45, the dose of the total bacteriophage administered is 1 x 10⁻¹⁰ 2 PFU / mL to 1X10 15 PFU / mL phosphorus, method to enhance antibiotic susceptibility of Pseudomonas aeruginosa.
49. A method for inhibiting or reducing a Pseudomonas aeruginosa biofilm, comprising the step of administering bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof to a site where a Pseudomonas aeruginosa biofilm has formed or is at risk of forming.
50. A method for inhibiting or reducing Pseudomonas aeruginosa biofilm according to claim 49, comprising the step of administering in combination with an antibiotic.
51. A method for inhibiting or reducing Pseudomonas aeruginosa biofilm according to claim 50, wherein the antibiotic comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof.
52. In paragraph 49, the dose of the total bacteriophage administered is 1 x 10⁻¹⁰ 2 PFU / mL to 1X10 15 A method to inhibit or reduce Pseudomonas aeruginosa biofilms in PFU / mL.
53. Use of bacteriophage MXP1001, bacteriophage MXP1002, or a mixture thereof capable of lysing Pseudomonas aeruginosa for the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection.
54. In paragraph 53, the use for the treatment, prevention, or improvement of a Pseudomonas aeruginosa infection or a disease associated with a Pseudomonas aeruginosa infection, wherein the disease associated with the Pseudomonas aeruginosa infection is one or more selected from the group consisting of pneumonia, lung abscess, bronchitis, pleuritis, meningitis, endocarditis, bacteremia, sepsis, and empyema.
55. In paragraph 53, use for the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection, further comprising antibiotics.
56. In paragraph 55, the antibiotic comprises a carbapenem antibiotic, an aminoglycoside antibiotic, a cephalosporin antibiotic, a tetracycline antibiotic, a fluoroquinolone antibiotic, a penicillin antibiotic, a nitrofuran antibiotic, a sulfonamide antibiotic, a monobactam antibiotic, a polymyxin antibiotic, or a combination thereof, for the treatment, prevention, or improvement of a Pseudomonas aeruginosa infection or a disease associated with a Pseudomonas aeruginosa infection.
57. In Paragraph 56, (a) The above carbapenem antibiotics include doripenem, ertapenem, imipenem, meropenem, imipenem / cilastatin / relebactam, imipenem / cilastatin, meropenem / baborbactam, or combinations thereof; (b) The above aminoglycoside antibiotics include amikacin, gentamicin, tobramycin, plasmomycin, aframycin, or a combination thereof; (c) The above cephalosporin antibiotic comprises cefazolin, ceftazidim, cefepim, ceftriaxone, cefiderocol, ceftazidim / avibactam, ceftolozane / tazobactam, cefotechitin, cefuroxim sodium, cefotaxim, ceftobiprol medocaryl sodium, or a combination thereof; (d) The tetracycline antibiotic comprises tigecycline, tetracycline, minocycline, or a combination thereof; (e) The above fluoroquinolone antibiotic comprises levofloxacin, ciprofloxacin, delafloxacin, gatifloxacin, lomefloxacin, pyrazino-oxazine, or a combination thereof; (f) The above penicillin antibiotic comprises piperacillin / tazobactam, ticarcillin / clavulanic acid, piperacillin, ampicillin / sulbactam, ampicillin, amoxicillin / clavulanic acid, ticarcillin, sulbactam / dulovactam, or a combination thereof; (g) The above nitrofuran antibiotic contains nitrofurantoin; (h) The above sulfonamide antibiotic is trimethoprim / sulfamethoxazole (TMP-SMX); (i) The monobactam antibiotic comprises aztreonam, aztreonam / avibactam, or a combination thereof; or (j) For the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection, wherein the above polymyxin antibiotic comprises colistin, polymyxin B, upleganan, MRX-8, QPX9003, or a combination thereof.
58. In paragraph 53, the total dose of the bacteriophage is 1 x 10⁻¹⁰ 2 PFU / mL to 1X10 15 PFU / mL phosphorus, use for the treatment, prevention, or improvement of Pseudomonas aeruginosa infection or diseases associated with Pseudomonas aeruginosa infection.
